Long-acting glp-1 compound

LT4086277TActive Publication Date: 2026-10-26
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LT4086277P0
Authority / Receiving Office
LT · LT
Patent Type
Patents
Priority Date
2020-09-29
Filing Date
2020-12-29
Publication Date
2026-10-26
Estimated Expiration
2040-12-29

AI Technical Summary

Technical Problem

Existing GLP-1 drugs have problems such as insufficient efficacy, high risk of side effects, short duration of action, and poor physical and chemical stability in the treatment of diabetes and obesity. Furthermore, there is still room for improvement in the frequency of administration and efficacy of existing combination formulations.

Method used

To develop a novel GLP-1 compound by modifying the Lys residue at position 26 of a GLP-1 analog with an amide bond of a specific aliphatic diacid and a neutral alkylene glycol amino acid residue, thereby forming a long-acting GLP-1 compound with better binding affinity and DPP-IV stability, and to combine it with acylated insulin to form a drug combination formulation with enhanced physical and chemical stability.

Benefits of technology

It achieves a longer duration of action in vivo, reduces the risk of side effects, improves the physical and chemical stability of the drug, and makes subcutaneous administration possible once a week or less frequently, thus enhancing the treatment effect for diabetic patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A novel GLP-1 derivative, compared with GLP-1 derivatives such as liraglutide and semaglutide which are on the market, has comparable or better effect, potency or efficacy, longer or comparable duration of action in vivo or half-life in vivo, has better or comparable GLP-1 receptor binding affinity, and has better or comparable DPP-IV stability.
Need to check novelty before this filing date? Find Prior Art

Description

Long-acting GLP-1 compounds TECHNICAL FIELD

[0001] The present application relates to the field of therapeutic peptides, in particular to novel long-acting GLP-1 compounds, pharmaceutical formulations thereof, pharmaceutical compositions of the same with long-acting insulin, and medical uses of the compounds, pharmaceutical formulations and pharmaceutical compositions. BACKGROUND

[0002] Glucagon-like peptide 1 (GLP-1) and its analogues and derivatives are very effective in the treatment of diabetes mellitus type 1 and type 2, however the high clearance rate limits the effectiveness of these compounds. In order to provide GLP-1 compounds with a longer duration of action in vivo, a series of different methods have been used to modify the structure of glucagon-like peptide 1 (GLP-1). For example, WO 99 / 43708 discloses GLP-1 (7-35) and GLP-1 (7-36) derivatives with a lipophilic substituent attached to the C-terminal amino acid residue. WO 00 / 34331 discloses acylated GLP-1 analogues. WO 00 / 69911 discloses activated insulinotropic peptides for injection into a patient.

[0003] Among the currently marketed GLP-1 drugs there are, for example, the native GLP-1 analogue Exenatide, which is administered twice a day; Liraglutide and Lixisenatide, which are administered once a day, the former being a hexadecanoic acid modified GLP-1 compound and the latter being a new molecule obtained by structural modification of Exenatide; and Semaglutide, Exenatide LAR, Abiglutide, Dulaglutide (also known as Dalaglutide) and Peglisozatide, which are administered once a week. Among these, Exenatide LAR is prepared by microencapsulation of Exenatide in a polylactic acid-glycolic acid copolymer matrix, Abiglutide is a recombinant fusion protein obtained by fusion of two modified GLP-1 peptide chains in dimeric form with human albumin; Dulaglutide is obtained by fusion of a modified GLP-1 chain to the Fc fragment of a recombinant G4 immunoglobulin via a disulphide bond; Peglisozatide is obtained by amino acid modification and polyethylene glycol modification on the basis of the chemical structure of Exenatide; Semaglutide is mainly obtained by replacing Ala at position 8 with the non-proteinogenic amino acid Aib in GLP-1 (7-37) peptide to achieve once-a-week administration, but the presence of non-proteinogenic amino acids in Semaglutide, as opposed to native amino acids, can pose unknown, various potential side effect risks in humans.

[0004] In one aspect, there is still a need to develop compounds that have better potency, efficacy, or effectiveness, have less risk of potential side effects, have better weight loss and appetite suppression effects, have longer or comparable in vivo duration of action or in vivo half-life, relative to the marketed drugs of the same class, such as liraglutide, dulaglutide, and semaglutide, to provide better medication options for diabetic patients.

[0005] In another aspect, there is a greater need for more effective drugs with simpler administration as the population of type 2 diabetes is rapidly increasing worldwide. For example, a combination formulation comprising both insulin and GLP-1 peptide as active ingredients can be a very effective therapeutic agent. Therefore, there is also still a need to be able to achieve a combination formulation with better physical and chemical stability, longer duration of action, and better efficacy.

[0006] SUMMARY

[0007] To overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative, the first aspect of the present application provides a new GLP-1 compound (also referred to as a GLP-1 derivative). The new GLP-1 compound has better potency, efficacy, or effectiveness, less risk of potential side effects, better weight loss effect, longer in vivo duration of action or in vivo half-life, better or comparable GLP-1 receptor binding affinity, and better or comparable DPP-IV stability, relative to the marketed GLP-1 derivatives such as liraglutide, dulaglutide, and semaglutide. And the long-acting GLP-1 compound of the present application and the pharmaceutical composition or combination formulation of the long-acting insulin provided by the present application not only do not weaken the physical stability of the GLP-1 compound and the insulin compound, but also the combination formulation has better physical stability than the single drug formulation. The physical stability of the combination formulation of the present application is unexpected compared to other combination formulations of long-acting GLP-1 compounds (such as combination formulations of liraglutide and degludec insulin). In addition, the combination formulation also increases the chemical stability of the GLP-1 compound and the acylated insulin compared to the single drug formulation. The GLP-1 compound of the present application, and the combination formulation containing the GLP-1 compound and the insulin compound provided by the present application, can both achieve good long pharmacokinetic (hereinafter also referred to as PK) characteristics, making it possible for diabetic patients to be treated subcutaneously twice a week, once a week, once every two weeks, or less frequently.

[0008] The GLP-1 compound provided by the first aspect of the present application is a compound of Formula B, or a pharmaceutically acceptable salt, amide, or ester thereof:

[0009] [Acy-(L1) r -(L2) q ]-G1 (B),

[0010] wherein G1is a GLP-1 analogue having Arg at position 34 and Ala or Gly at position 8 corresponding to GLP-1 (7-37) (SEQ ID NO: 1), [Acy-(L1) r -(L2) q ] is a substituent attached to the epsilon amino group of a Lys residue at position 26 of said GLP-1 analogue, wherein

[0011] r is an integer from 1 to 10, q is 0 or an integer from 1 to 10;

[0012] Acy is an aliphatic diacid comprising 20 to 24 carbon atoms, wherein a hydroxyl group has been removed formally from one of the carboxyl groups of said aliphatic diacid;

[0013] L1is an amino acid residue selected from the group consisting of γGlu, αGlu, βAsp, αAsp, γ-D-Glu, α-D-Glu, β-D-Asp or α-D-Asp;

[0014] L2is a neutral, alkylene glycol-comprising amino acid residue;

[0015] Acy, L1, and L2are connected in amide bonds between each other; and

[0016] The order in which L1and L2occur in formula (B) can be independently interchanged.

[0017] In one embodiment, G1is a [Gly8,Arg34]GLP-1-(7-37) peptide or a [Arg34]GLP-1-(7-37) peptide, preferably a [Gly8,Arg34]GLP-1-(7-37) peptide.

[0018] In one embodiment, r is 1, 2, 3, 4, 5 or 6, preferably r is 1, 2, 3 or 4, preferably r is 1 or 2, preferably r is 1.

[0019] In another embodiment, q is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably q is 0, 1, 2, 3 or 4, more preferably q is 0, 1, or 2.

[0020] In one embodiment, Acy is an aliphatic diacid comprising 20 to 23 carbon atoms, preferably Acy is an aliphatic diacid comprising 20, 21, or 22 carbon atoms, wherein a hydroxyl group has been removed formally from one of the carboxyl groups of said aliphatic diacid.

[0021] In one embodiment, L2 is: -HN-(CH2)2-O-(CH2)2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-CH2-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)3-O-CH2-CO-, or -HN-(CH2)4-O-(CH2)4-O-CH2-CO-; preferably L2 is -HN-(CH2)2-O-(CH2)2-O-CH2-CO-.

[0022] In one embodiment, L1 is selected from γGlu or βAsp, preferably L1 is γGlu.

[0023] In one embodiment, Acy is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 19 -CO-, HOOC-(CH2) 20 -CO-, HOOC-(CH2) 21-CO- or HOOC-(CH2) 22 -CO-, Acy is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 20 -CO- or HOOC-(CH2) 22 -CO-.

[0024] In one embodiment, Acy, L1, and L2 in formula (B) are sequentially linked by amide bonds, and the C-terminal end of L2 is attached to the epsilon amino group of the Lys residue at position 26 of the GLP-1 analogue.

[0025] In one embodiment, the compound according to the first aspect of the application is selected from the following compounds:

[0026] N-epsilon 26 -[2-(2-[2-(2-[2-(2-[4-(19-carboxy-nonadecanoylamino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0027] N-epsilon 26 -[2-(2-[2-(4-[19-carboxy-nonadecanoylamino]-4(S)-carboxy-butyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0028] N-epsilon 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxy-heneicosanoylamino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0029] N-epsilon 26 -[2-(2-[2-(4-[21-carboxy-heneicosanoylamino]-4(S)-carboxy-butyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0030] N-epsilon 26 -[2-(2-[2-(2-[2-(2-[4-(23-carboxy-tricosanoylamino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0031] N-epsilon 26-[2-(2-[2-(4-[23-carboxytricosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0032] N-ε 26 -(23-carboxytricosanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34] GLP-1 -(7-37) peptide,

[0033] N-ε 26 -(19-carboxynonadecanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34] GLP-1 -(7-37) peptide,

[0034] N-ε 26 -(21-carboxyheneicosanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34] GLP-1 -(7-37) peptide,

[0035] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(19-carboxynonadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0036] N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0037] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0038] N-ε 26 -[2-(2-[2-(4-[21-carboxyheneicosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0039] N-ε 26-[2-(2-[2-(2-[2-(2-[4-(23-carboxytricosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1 -(7-37) peptide,

[0040] N-ε 26 -[2-(2-[2-(4-[23-carboxytricosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1 -(7-37) peptide,

[0041] N-ε 26 -(23-carboxytricosanoylamino)-4(S)-carboxybutyryl-[Arg34]GLP-1 -(7-37) peptide,

[0042] N-ε 26 -(19-carboxynonadecanoylamino)-4(S)-carboxybutyryl-[Arg34]GLP-1 -(7-37) peptide, or

[0043] N-ε 26 -(21-carboxyheneicosanoylamino)-4(S)-carboxybutyryl-[Arg34]GLP-1 -(7-37) peptide.

[0044] In one embodiment, the compound according to the first aspect of the application is selected from the following compounds:

[0045] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(19-carboxynonadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1 -(7-37) peptide,

[0046] N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1 -(7-37) peptide,

[0047] N-ε 26 -(19-carboxynonadecanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34]GLP-1 -(7-37) peptide,

[0048] N-ε 26 -(19-carboxynonadecanoylamino)-4(S)-carboxybutyryl-[Arg34]GLP-1 -(7-37) peptide,

[0049] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0050] N-ε 26 -[2-(2-[2-(4-[21-carboxyheneicosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0051] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(20-carboxyicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0052] N-ε 26 -[2-(2-[2-(4-[20-carboxyicosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0053] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(22-carboxydocosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0054] N-ε 26 -[2-(2-[2-(4-[22-carboxydocosanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide,

[0055] N-ε 26 -(20-carboxyicosanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34] GLP-1 -(7-37) peptide,

[0056] N-ε 26 -(22-carboxydocosanoylamino)-4(S)-carboxybutyryl-[Gly8, Arg34] GLP-1 -(7-37) peptide,

[0057] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(20-oxaheptadecanoyl amino)-4(S)-carboxybutyryl amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0058] N-ε 26 -[2-(2-[2-(4-[20-oxaheptadecanoyl amino]-4(S)-carboxybutyryl amino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0059] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(22-oxatetracosanoyl amino)-4(S)-carboxybutyryl amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0060] N-ε 26 -[2-(2-[2-(4-[22-oxatetracosanoyl amino]-4(S)-carboxybutyryl amino)ethoxy]ethoxy)acetyl][Arg34] GLP-1 -(7-37) peptide,

[0061] N-ε 26 -(20-oxaheptadecanoyl amino)-4(S)-carboxybutyryl-[Arg34] GLP-1 -(7-37) peptide, or

[0062] N-ε 26 -(22-oxatetracosanoyl amino)-4(S)-carboxybutyryl-[Arg34] GLP-1 -(7-37) peptide.

[0063] In one embodiment, the compound according to the first aspect of the application is selected from the following compounds:

[0064] N-ε 26 -[2-(2-[2-(4-[19-oxononadecanoyl amino]-4(S)-carboxybutyryl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide, or N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-oxaheneicosanoyl amino)-4(S)-carboxybutyryl amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide.

[0065] The second aspect of the application provides a pharmaceutical formulation comprising a compound according to the first aspect of the application and a pharmaceutically acceptable excipient.

[0066] In one embodiment, the pharmaceutically acceptable excipient is selected from one or more of a buffer, a preservative, an isotonicity agent, a stabilizer and a chelating agent. In another embodiment, the pharmaceutically acceptable excipient is a buffer, a preservative and an isotonicity agent.

[0067] In one embodiment, the pharmaceutical formulation comprises a compound according to the first aspect of the application, an isotonicity agent, a preservative and a buffer. Preferably, in the pharmaceutical formulation, the compound according to the first aspect of the application is N-ε 26 -[2-(2-[2-(4-[19-carboxy-nonadecanoylamino]-4(S)-carboxy-butyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide, or N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxy-heneicosanoylamino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetyl-amino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide.

[0068] In one embodiment, the isotonicity agent is selected from one or more of sodium chloride, propylene glycol, mannitol, sorbitol, glycerol, glucose and xylitol, preferably propylene glycol, mannitol or sodium chloride.

[0069] In another embodiment, the preservative is selected from one or more of phenol, m-cresol, methyl paraben, propyl paraben, 2-phenoxyethanol, butyl paraben, 2-phenylethanol, and benzyl alcohol, preferably phenol or m-cresol.

[0070] In another embodiment, the buffer is selected from one or more of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate, and tris(hydroxymethyl)-aminomethane, preferably sodium acetate, citrate, sodium phosphate monobasic, or sodium phosphate dibasic.

[0071] In one embodiment, the pH of the formulation is from about 6.0 to about 10.0, preferably from about 6.5 to about 10.0, preferably from about 6.5 to about 9.5, preferably from about 6.5 to about 8.5, more preferably from about 7.0 to about 8.5, more preferably from about 7.0 to about 8.1, further preferably from about 7.3 to about 8.1.

[0072] In one embodiment, the pharmaceutical formulation comprises:

[0073] about 0.1-1.2 mM, preferably about 0.2-1 mM, preferably about 0.3-0.7 mM, more preferably about 0.48-0.6 mM, of a compound according to the first aspect of the present application;

[0074] about 10-1500 mM, preferably about 13-800 mM, preferably about 65-400 mM, preferably about 90-240 mM, preferably about 150-250 mM, preferably about 180-200 mM, more preferably about 183-195 mM, of an isotonic agent, preferably the isotonic agent is selected from one or more of propylene glycol, glycerol, mannitol or sodium chloride;

[0075] about 1-200 mM, preferably about 5-150 mM, preferably about 10-100 mM, preferably about 20-85 mM, preferably about 30-75 mM, preferably about 45-60 mM, more preferably about 50-60 mM, of a preservative, preferably the preservative is selected from one or more of phenol or m-cresol;

[0076] about 3-35 mM, preferably about 5-20 mM, more preferably about 5-15 mM, more preferably about 7-10 mM, of a buffer selected from one or more of sodium acetate, citrate, sodium phosphate monobasic or sodium phosphate dibasic; and

[0077] the pH of the pharmaceutical formulation is about 6.0 to about 10.0, preferably about 6.5 to about 9.5, preferably about 6.5 to about 8.5, more preferably about 7.0 to about 8.5, more preferably about 7.0 to about 8.1, further preferably about 7.3 to about 8.1.

[0078] In another experimental protocol, the pharmaceutical formulation comprises: about 0.3-0.7 mM, more preferably about 0.48-0.6 mM, of N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1 -(7-37) peptide or N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1 -(7-37) peptide; about 180-200 mM, more preferably about 183-195 mM, of propylene glycol; about 45-60 mM, more preferably about 50-60 mM, of phenol; about 5-15 mM of a buffer, preferably about 7-10 mM of sodium phosphate dibasic; and the pH of the pharmaceutical formulation is about 6.5 to about 8.5, more preferably about 7.0 to about 8.5, further preferably about 7.3 to about 8.3.

[0079] In another experimental protocol, the pharmaceutical formulation comprises: about 0.5 mM of N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyhenicosanoyl-amino)-4(S)-carboxybutyryl- amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7- 37) peptide or N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoyl-amino]-4(S)-carboxybutyryl-amino)ethoxy] ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide; about 184 mM propylene glycol; about 58.5 mM phenol; about 10 mM disodium hydrogen phosphate; and the pH of the pharmaceutical formulation is about 6.5 to about 8.5, more preferably about 7.0 to about 8.5, more preferably about 7.0 to about 8.1, further preferably about 7.3 to about 8.1.

[0080] In another experimental protocol, the pharmaceutical formulation comprises: about 2.0 mg / ml of N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyhenicosanoyl-amino)-4(S)-carboxybutyryl- amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7- 37) peptide or N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoyl-amino]-4(S)-carboxybutyryl-amino)ethoxy] ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide; about 14 mg / ml propylene glycol; about 5.5 mg / ml phenol; about 1.42 mg / ml disodium hydrogen phosphate; and

[0081] the pH of the pharmaceutical formulation is about 6.5 to about 8.5, more preferably about 7.0 to about 8.5, more preferably about 7.0 to about 8.1, further preferably about 7.3 to about 8.1.

[0082] A third aspect of the present application provides a pharmaceutical composition comprising a GLP-1 compound according to the first aspect of the present application, and an acylated insulin.

[0083] In one embodiment, the acylated insulin is B29K(N(ε)-eicosanedioyl-γGlu-OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-2xOEG), desB30 human insulin; or B29K(N(ε)-eicosanedioyl-γGlu-12xPEG), desB30 human insulin.

[0084] In one embodiment, the acylated insulin is an insulin wherein the insulin parent is a naturally occurring insulin or an insulin analogue, and comprises at least one lysine residue, and the acyl moiety of the acylated insulin is attached to the amino group of a lysine residue or the N-terminal amino acid residue of the insulin parent, the acyl moiety being as shown in formula (A):

[0085] III-(II) m -(I) n -(A), wherein m is 0 or an integer from 1 to 10, n is an integer from 5 to 20; I is a neutral, alkyleneglycol-containing amino acid residue; II is an acidic amino acid residue; III is an aliphatic diacid comprising 20 to 24 carbon atoms, wherein a hydroxyl group has been formally removed from one of the carboxyl groups of the aliphatic diacid; III, II, and I are linked by amide bonds; and the order in which II and I appear in formula (A) can be independently interchanged.

[0086] In one embodiment, n is 5 to 15, preferably, n is 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, preferably, n is 5, 6, 7, 8, 9, 10, 11, or 12, preferably, n is 5, 6, 7, 8, 9, or 10, preferably, n is 5, 6, 7, 8, or 9, preferably, n is 5, 6, 7, or 8.

[0087] In another embodiment, m is 1 to 6, preferably, m is 1, 2, 3, or 4, preferably, m is 1 or 2, preferably, m is 1.

[0088] In yet another embodiment, III is an aliphatic diacid comprising 20 to 23 carbon atoms, preferably III is an aliphatic diacid comprising 20, 21, or 22 carbon atoms, wherein a hydroxyl group has been formally removed from one of the carboxyl groups of the aliphatic diacid.

[0089] In another embodiment, the insulin parent comprises one lysine residue.

[0090] In one embodiment, I is: -HN-(CH2)2-O-(CH2)2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-CH2-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)3-O-CH2-CO-, or -HN-(CH2)4-O-(CH2)4-O-CH2-CO-; preferably I is -HN-(CH2)2-O-(CH2)2-O-CH2-CO-.

[0091] In another embodiment, II is an amino acid residue selected from the group consisting of γGlu, αGlu, βAsp, αAsp, γ-D-Glu, α-D-Glu, β-D-Asp, or α-D-Asp; preferably, II is selected from γGlu or βAsp.

[0092] In another embodiment, III is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 19-CO-, HOOC-(CH2) 20 -CO-, HOOC-(CH2) 21 -CO-, HOOC-(CH2) 22 -CO-, HOOC-(CH2) 18 -CO-, HOOC-(CH2) 20 -CO-, HOOC-(CH2) 22 -CO-.

[0093] In one embodiment, Formula (A) is attached to the amino group of a lysine residue or the N-terminal amino acid residue of the insulin parent via the C-terminal of I.

[0094] In one embodiment, the acyl moiety is attached to the epsilon amino group of a lysine residue of the insulin parent.

[0095] In one embodiment, the lysine residue of the insulin parent is at position B29.

[0096] In one embodiment, the insulin parent is selected from the following insulins or insulin analogs: desB30 human insulin (SEQ ID NO: 4 and SEQ ID NO: 5, representing the A and B chains, respectively); A14E, B16H, B25H, desB30 human insulin (SEQ ID NO: 6 and SEQ ID NO: 7, representing the A and B chains, respectively); A14E, B16E, B25H, desB30 human insulin (SEQ ID NO: 8 and SEQ ID NO: 9, representing the A and B chains, respectively); human insulin (SEQ ID NO: 10 and SEQ ID NO: 11, representing the A and B chains, respectively); A21G human insulin (SEQ ID NO: 12 and SEQ ID NO: 13, representing the A and B chains, respectively); A21G, desB30 human insulin (SEQ ID NO: 14 and SEQ ID NO: 15, representing the A and B chains, respectively); or B28D human insulin (SEQ ID NO: 16 and SEQ ID NO: 17, representing the A and B chains, respectively).

[0097] In one embodiment, the acylated insulin is selected from the following insulins: B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-8xOEG), desB30 human insulin;B29K(N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-5xOEG-γGlu), desB30 human insulin; B29K(N(ε)-docosanedioyl-6xOEG-γGlu), desB30 human insulin; B29K(N(ε)-docosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-docosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-docosanedioyl-βAsp-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-βAsp-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αAsp-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin;B29K(N(ε)-octadecanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-octadecanedioyl-βAsp-7xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-βAsp-8xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αAsp-7xOEG), desB30 human insulin; B29K(N(ε)-octadecanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-octadecanedioyl-βAsp-8xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-βAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; B29K(N(ε)-heneicosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-heneicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-heneicosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-heneicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-tricosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-tricosanedioyl-γGlu-6xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tricosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tricosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-tetracosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-tetracosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-8xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-tetradocosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetradocosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetradocosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetradocosanedioyl-γGlu-12xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-9xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-eicosanedioyl-γGlu-11xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanedioyl-γGlu-9xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanedioyl-γGlu-11xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tricosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanedioyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-9xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-11xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-9xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-11xOEG), desB30 human insulin; B29K(N(ε)-heneicosanedioyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-tricosanedioyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-tetracosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-18xOEG), desB30 human insulin; or A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-24xOEG), desB30 human insulin.

[0098] The inventors surprisingly found that the compound and the pharmaceutical composition of acylated insulin according to the first aspect of the present application not only do not weaken the physical stability of the compound, but also the combined preparation has better physical stability than the single drug preparation. The physical stability of the combined preparation of the present application is surprising compared to the combined preparations of other long-acting insulin derivatives (e.g. degludec and liraglutide). In addition, the combined preparation also increases the chemical stability of the acylated insulin compared to the single drug preparation.

[0099] The fourth aspect of the present application provides the use of the compound according to the first aspect of the present application, the pharmaceutical preparation according to the second aspect of the present application or the pharmaceutical composition according to the third aspect of the present application as a medicament.

[0100] In one embodiment, the compound according to the first aspect of the present application, the pharmaceutical preparation according to the second aspect of the present application or the pharmaceutical composition according to the third aspect of the present application is used for the treatment or prevention of hyperglycemia, diabetes, and / or obesity.

[0101] The fifth aspect of the present application provides the use of the compound according to the first aspect of the present application, the pharmaceutical preparation according to the second aspect of the present application or the pharmaceutical composition according to the third aspect of the present application in the preparation of a medicament for the treatment or prevention of hyperglycemia, diabetes, and / or obesity.

[0102] The sixth aspect of the present application provides a method for the treatment or prevention of hyperglycemia, diabetes, and / or obesity, which comprises administering an effective amount of the compound according to the first aspect of the present application, the pharmaceutical preparation according to the second aspect of the present application or the pharmaceutical composition according to the third aspect of the present application, including but not limited to, for example, hyperglycemia, diabetes and obesity. BRIEF DESCRIPTION OF DRAWINGS

[0103] Figure 1a shows the hypoglycemic effect and action time of the title compound of Examples 1-3 of the present application, liraglutide, and vehicle on db / db mice, wherein the percentage of the ordinate refers to the percentage of blood glucose at each monitoring point after administration compared with the baseline blood glucose before administration.

[0104] Figure 1b shows the AUC of the hypoglycemic effect of the title compound of Examples 1-3 of the present application, liraglutide, and vehicle on db / db mice, corresponding to Figure 1a.

[0105] Figure 2a shows the hypoglycemic effect and action time of the title compound of Example 2 of the present application, semaglutide, and vehicle on db / db mice.

[0106] Figure 2b shows the AUC of the glucose-lowering effect of the title compound of Example 2 of the present invention, semaglutide, and vehicle on db / db mice, corresponding to Figure 2a.

[0107] Figure 3a shows the glucose-lowering effect and duration of action of the title compound of Example 3-4 of the present invention, liraglutide, and vehicle on db / db mice.

[0108] Figure 3b shows the AUC of the glucose-lowering effect of the title compound of Example 3-4 of the present invention, liraglutide, and vehicle on db / db mice, corresponding to Figure 3a.

[0109] Figure 4a shows the glucose-lowering effect and duration of action of the title compound of Examples 1-3 of the present invention, the title compound of Comparative Examples 3-4, and vehicle on db / db mice.

[0110] Figure 4b shows the AUC of the glucose-lowering effect of the title compound of Examples 1-3 of the present invention, the title compound of Comparative Examples 3-4, and vehicle on db / db mice, corresponding to Figure 4a.

[0111] Figure 5a shows the glucose-lowering effect and duration of action of the title compound of Example 11 of the present invention at doses of 100 μg / kg and 300 μg / kg, the title compound of Comparative Example 2, and vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control).

[0112] Figure 5b shows the AUC of the glucose-lowering effect of the title compound of Example 11 of the present invention, the title compound of Comparative Example 2, and vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control), corresponding to Figure 5a.

[0113] Figure 5c shows the weight loss effect of the title compound of Example 11 of the present invention, the title compound of Comparative Example 2, and vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control).

[0114] Figure 6a shows the glucose-lowering effect of the title compound of Example 11 of the present invention, the title compound of Comparative Example 2, and vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control) at 48 hours after the first administration when ipGTT was performed.

[0115] Figure 6b shows the △AUC of the glucose-lowering effect of the title compound of Example 11 of the present invention, the title compound of Comparative Example 2, and vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control) at 48 hours after the first administration when ipGTT was performed, corresponding to Figure 6a.

[0116] Figure 7a shows the glucose-lowering effect of the title compound of Example 2 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0117] Figure 7b shows the ΔAUC of the glucose-lowering effect of the title compound of Example 2 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice, corresponding to Figure 7a.

[0118] Figure 7c shows the food intake control effect of the title compound of Example 2 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0119] Figure 7d shows the water intake control effect of the title compound of Example 2 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0120] Figure 8a shows the long-term glucose-lowering effect of the title compound of Example 11 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0121] Figure 8b shows the AUC of the long-term glucose-lowering effect of the title compound of Example 11 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice, corresponding to Figure 8a.

[0122] Figure 8c shows the long-term weight loss effect of the title compound of Example 11 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0123] Figure 8d shows the long-term food intake control effect of the title compound of Example 11 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0124] Figure 8e shows the long-term water intake control effect of the title compound of Example 11 of the present application, the title compound of Comparative Example 2, and the vehicle on db / db mice.

[0125] Figure 9a shows the glucose-lowering effect of the title compound of Example 11 of the present application, the title compound of Example 2, dulaglutide, and the vehicle on Kkay mice.

[0126] Figure 9b shows the AUC of the glucose-lowering effect of the title compound of Example 11 of the present application, the title compound of Example 2, dulaglutide, and the vehicle on Kkay mice, corresponding to Figure 9a.

[0127] Figure 9c shows the HbAlc-lowering effect of the title compound of Example 11 of the present application, the title compound of Example 2, dulaglutide, and the vehicle on Kkay mice.

[0128] Figure 10a shows the long-term glucose-lowering effect of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) on db / db mice or normal mice (normal control).

[0129] Figure 10b shows the ΔAUC of the long-term glucose-lowering effect of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) on db / db mice or normal mice (normal control) corresponding to Figure 10a.

[0130] Figure 10c shows the random blood glucose values before administration, third, fifth and tenth injection of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) in db / db mice or normal mice (normal control).

[0131] Figure 10d shows the glucose-lowering effect of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) on db / db mice or normal mice (normal control group) at 48 hours after the first administration when ipGTT was performed.

[0132] Figure 10e shows the AUC of the glucose-lowering effect of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) on db / db mice or normal mice (normal control group) at 48 hours after the first administration when ipGTT was performed corresponding to Figure 10d.

[0133] Figure 11a shows the long-term weight loss effect of the title compound of Example 11 of the present application, dulaglutide, vehicle (model control group) on high-fat diet-induced obese C57BL mice or normal mice (normal control group).

[0134] Figure 11b shows the long-term food intake control effect of the title compound of Example 11 of the present application, dulaglutide and vehicle (model control group) on high-fat diet-induced obese C57BL mice.

[0135] Figure 11c shows the reduction effect of periovarian fat of the title compound of Example 11 of the present application, dulaglutide and vehicle (model control group) on high-fat diet-induced obese C57BL female mice.

[0136] Figure 11d shows the reduction effect of epididymal fat of the title compound of Example 11 of the present application, dulaglutide and vehicle (model control group) on high-fat diet-induced obese C57BL male mice. DETAILED DESCRIPTION

[0137] DEFINITIONS

[0138] GLP-1 analogs, and GLP-1 derivatives

[0139] The term "GLP-1 analogue" or "analog of GLP-1" as used herein refers to a peptide or a compound which is a variant of human glucagon-like peptide-1 (GLP-1 (7-37)) in which one or more amino acid residues of GLP-1 (7-37) are replaced, and / or in which one or more amino acid residues are deleted, and / or in which one or more amino acid residues are added. In particular, the sequence of GLP-1 (7-37) is as set forth in SEQ ID NO: 1 in the sequence listing. The peptide having the sequence set forth in SEQ ID NO: 1 can also be referred to as "native" GLP-1 or "native" GLP-1 (7-37).

[0140] In the sequence listing, the first amino acid residue of SEQ ID NO: 1 (histidine) is numbered 1. However, in the following, in accordance with established custom in the art, this histidine residue is numbered as 7, and the amino acid residues following are numbered accordingly, ending with glycine number 37. Thus, generally, the amino acid residue numbering or position numbering of the GLP-1 (7-37) sequence referred to herein is the sequence starting with His at position 7 and ending with Gly at position 37.

[0141] The [Gly8, Arg34] GLP-1 -(7-37) peptide is a GLP-1 analogue having a Gly and an Arg at positions corresponding to position 8 and position 34 of GLP-1 (7-37) (SEQ ID NO: 1), respectively, the [Arg34] GLP-1 -(7-37) peptide is a GLP-1 analogue having an Arg at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1). In particular, the amino acid sequences of the [Gly8, Arg34] GLP-1 -(7-37) peptide and the [Arg34] GLP-1 -(7-37) peptide are as set forth in SEQ ID NO: 2 and SEQ ID NO: 3 in the sequence listing, respectively.

[0142] The term "derivative" as used herein in the context of a GLP-1 peptide or an analogue thereof refers to a GLP-1 peptide or analogue which is chemically modified in that one or more substituents have been covalently attached to the peptide. The substituents can also be referred to as side chains.

[0143] Unless otherwise indicated, when referring to acylation with a lysine residue, it is understood to be with its epsilon-amino group.

[0144] The GLP-1 derivatives of formula (B) of the present application can exist in different stereoisomeric forms having the same molecular formula and sequence of atoms linked, but differing only in the spatial, three-dimensional orientation of their atoms. Unless otherwise specified, the present application is directed to all stereoisomeric forms of the claimed derivatives.

[0145] The term "peptide" when used in relation to, for example, the GLP-1 analogues of the application, refers to a compound comprising a series of amino acids linked to each other by amide (or peptide) bonds.

[0146] In one particular embodiment, the peptide consists largely or predominantly of amino acids linked to each other by amide bonds (e.g. at least 50%, 60%, 70%, 80% or at least 90% of the molar mass). In another particular embodiment, the peptide consists of amino acids linked to each other by peptide bonds.

[0147] An amino acid is a molecule containing an amino group and a carboxylic acid group, optionally containing one or more additional groups, usually referred to as side chains.

[0148] The term "amino acid" encompasses proteinogenic amino acids (encoded by the genetic code, including natural amino acids and standard amino acids), as well as non-proteinogenic (not found in proteins and / or not encoded in the standard genetic code), and synthetic amino acids. Non-proteinogenic amino acids are moieties that can be integrated into a peptide by a peptide bond, but are not proteinogenic amino acids. Synthetic non-proteinogenic amino acids include amino acids produced by chemical synthesis, i.e. D-isomers of the amino acids encoded by the genetic code, such as D-alanine and D-leucine, Aib (alpha-aminoisobutyric acid), Abu (alpha-aminobutyric acid), 3-aminomethylbenzoic acid, anthranilic acid, desamino-histidine, beta-analogues of amino acids such as beta-alanine, etc., D-histidine, desamino-histidine, 2-amino-histidine, beta-hydroxy-histidine, and homohistidine, etc.

[0149] Non-limiting examples of amino acids not encoded by the genetic code are gamma-carboxyglutamate, ornithine, D-alanine, D-glutamine and phosphoserine. Non-limiting examples of synthetic amino acids are D-isomers of the amino acids, such as D-alanine and D-leucine, Aib (alpha-aminoisobutyric acid), beta-alanine and des-amino-histidine (desH, alternative name imidazole propionic acid, abbreviation Imp).

[0150] In the following, all amino acids not specified for the optical isomer are understood to refer to the L-isomer (unless otherwise specified).

[0151] Pharmaceutically acceptable salts, amides or esters

[0152] The GLP-1 derivatives, analogs, and intermediates of the present application can be in the form of a pharmaceutically acceptable salt, amide, or ester. The salt can be a basic salt, an acid salt, or a neutral salt. Basic salts yield the hydroxyl ion in water, and acid salts yield the hydronium ion. Salts of the derivatives of the present application can be formed with added cations or anions that react with the anionic or cationic groups, respectively. These groups can be located within the peptide portion and / or in the side chains of the derivatives of the present application.

[0153] Non-limiting examples of anionic groups of the derivatives of the present application include free carboxyl groups in the side chains, if any, and in the peptide portion. The peptide portion typically includes a free carboxylic acid at the C-terminus, and it can also include free carboxyl groups on internal acidic amino acid residues such as Asp and Glu.

[0154] Non-limiting examples of cationic groups of the peptide portion include a free amino group at the N-terminus, if any, and any free amino groups on internal basic amino acid residues such as His, Arg, and Lys.

[0155] Esters of the derivatives of the present application can be formed, for example, by reaction of a free carboxylic acid group with an alcohol or phenol, which results in replacement of at least one hydroxyl group with an alkoxy or aryloxy group. The formation of an ester can involve the free carboxyl group at the C-terminus of the peptide, and / or any free carboxyl groups of the side chains.

[0156] Amides of the derivatives of the present application can be formed, for example, by reaction of a free carboxylic acid group with an amine or substituted amine, or by reaction of a free or substituted amino group with a carboxylic acid. The formation of an amide can involve the free carboxyl group at the C-terminus of the peptide, any free carboxyl groups of the side chains, the free amino group at the N-terminus of the peptide, and / or any free or substituted peptide amino groups in the peptide and / or side chains.

[0157] In one particular embodiment, the GLP-1 compound or GLP-1 derivative of the present application is in the form of a pharmaceutically acceptable salt. In another particular embodiment, it is in the form of a pharmaceutically acceptable amide, preferably having an amide group at the C-terminus of the peptide. In still further particular embodiments, the peptide or derivative is in the form of a pharmaceutically acceptable ester.

[0158] Methods for the preparation of the GLP-1 (7-37) peptide and GLP-1 analogs of the present application are well known in the art. For example, the GLP-1 peptide portion (or fragment thereof) of the derivatives of the present application as well as the GLP-1 analogs of the present application can be produced by classical peptide synthesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see, e.g. Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1999, Florencio Zaragoza "Organic Synthesis on solid Phase", Wiley-VCH Verlag GmbH, 2000, and "Fmoc Solid Phase Peptide Synthesis", by W.C. Chan and P.D. White, Oxford University Press, 2000.

[0159] In one embodiment, the intact GLP-1 analogs of the present application, e.g. the [Gly8, Arg34] GLP-1 -(7-37) peptide, can be produced by recombinant methods, i.e. by culturing host cells which contain a DNA sequence encoding the analog and which are capable of expressing the peptide in a suitable nutrient medium under conditions permitting the expression of the peptide. Non-limiting examples of suitable host cells for the expression of these peptides are: Escherichia coli, Saccharomyces cerevisiae, and mammalian BHK or CHO cell lines. In some embodiments, this fully recombinant fermentation step of the production process is desirable, e.g. for production economy reasons.

[0160] The fusion protein inclusion bodies containing the GLP-1 compound main chain are denatured, renatured to obtain the fusion protein containing the correct conformation, and then subjected to a series of treatments such as enzyme digestion, dialysis, centrifugation, etc. to obtain the GLP-1 compound main chain with a higher content. The GLP-1 compound main chain with a higher purity is obtained after ion exchange chromatography purification and treatment.

[0161] The term "excipient" broadly refers to any ingredient other than the active therapeutic ingredient. An excipient can be an inert or inactive substance and / or a substance that is not pharmaceutically active.

[0162] Excipients can be used for a variety of purposes, e.g. as carriers, vehicles, diluents, tabletting aids, and / or for improving administration, and / or absorption of the active substance.

[0163] The formulation of pharmaceutical active ingredients with different excipients is known in the art, see e.g. Remington: The Science and Practice of Pharmacy (e.g. 19thedition (1995), and any newer edition).

[0164] Non-limiting examples of excipients are solvents, diluents, buffers, preservatives, isotonic agents, chelating agents and stabilizers.

[0165] The GLP-1 derivatives and analogs of the present application have GLP-1 activity. Having GLP-1 activity means the ability to bind to the GLP-1 receptor and to initiate the signal transduction pathway resulting in a insulinotropic effect or other physiological effect.

[0166] In a particular embodiment, potency, efficacy and / or activity means in vitro efficacy, i.e. performance in a functional GLP-1 receptor assay, more particularly the ability to stimulate cAMP formation in a cell line expressing a cloned human GLP-1 receptor.

[0167] In another particular embodiment, the derivatives of the present application are potent in vivo, which can be determined in any suitable animal model as well as in clinical trials following art-known procedures. Diabetic db / db mice are for example a suitable animal model in which blood glucose lowering effects can be determined, e.g. as described in the Examples section of the present application.

[0168] The term "insulin" includes naturally occurring insulins, such as human insulin, as well as insulin analogs, insulin derivatives thereof.

[0169] The term "insulin analog" comprises a polypeptide which has a molecular structure derived from the structure of a naturally occurring insulin (e.g. human insulin) in form that one or more amino acid residues present in the naturally occurring insulin are deleted and / or replaced (substituted) and / or at least one amino acid residue is added. Preferably, the replaced amino acid residue is a codable amino acid residue.

[0170] Herein, the term "insulin derivative" refers to a naturally occurring insulin or an insulin analog which has been chemically modified, e.g. by introducing a side chain at one or more positions of the insulin backbone or by oxidizing or reducing a group of an amino acid residue of the insulin or by converting a free carboxyl group into an ester group or acylating a free amino or hydroxyl group. The acylated insulins of the present application are insulin derivatives.

[0171] The term "insulin parent" refers to the insulin part of an insulin derivative or acylated insulin (also referred to herein as parent insulin), e.g. in the present application to the part of the acylated insulin without the additional acyl group. The insulin parent can be a naturally occurring insulin, such as human insulin or porcine insulin. Alternatively, the parent insulin can be an insulin analogue.

[0172] Herein, the term "amino acid residue" comprises an amino acid from which a hydrogen atom has been removed from the amino group and / or a hydroxyl group has been removed from the carboxyl group and / or a hydrogen atom has been removed from the thiol group. Imprecisely, an amino acid residue can be called an amino acid.

[0173] Unless otherwise indicated, the amino acids referred to herein are L-amino acids.

[0174] Herein, the term "alkylene glycol" comprises oligo- and polyalkylene glycol moieties as well as monoalkylene glycol moieties. Mono- and polyalkylene glycols include e.g. chains based on mono- and polyethylene glycol, mono- and polypropylene glycol, and mono- and polybutylene glycol, i.e. chains based on the repeating units -CH2CH2O-, -CH2CH2CH2O- or -CH2CH2CH2CH2O-. The alkylene glycol moieties can be monodisperse (with a well-defined length / molecular weight) as well as polydisperse (with a less well-defined length / average molecular weight). The monoalkylene glycol moieties include -OCH2CH2O-, -OCH2CH2CH2O- or -OCH2CH2CH2CH2O- comprising different groups at each end.

[0175] The term "fatty acid" includes straight-chain or branched aliphatic carboxylic acids having at least two carbon atoms and being saturated or unsaturated. Non-limiting examples of fatty acids are e.g. myristic acid, palmitic acid, stearic acid and arachidic acid.

[0176] Herein, the term "aliphatic diacid" includes straight-chain or branched aliphatic dicarboxylic acids having at least two carbon atoms and being saturated or unsaturated. Non-limiting examples of aliphatic diacids are adipic acid, suberic acid, sebacic acid, dodecanedioic acid, tetradecanedioic acid, hexadecanedioic acid, heptadecanedioic acid, octadecanedioic acid, eicosanedioic acid, docosanedioic acid and tetracosanedioic acid.

[0177] In the present text, the nomenclature of the insulin or GLP-1 compounds is given according to the following principles: The mutations and modifications (e.g. acylations) relative to human insulin, or the mutations and modifications (e.g. acylations) of the native GLP-1 (7-37) are given the name. For the nomenclature of the acyl moieties, the IUPAC nomenclature is followed and in other cases the nomenclature of peptides. For example, the following acyl moieties are named:

[0178]

[0179] may be named, for example, "Arachidoyl-gGlu-OEG-OEG", "Arachidoyl-gGlu-2xOEG" or "Arachidoyl-gGlu-2xOEG", "19-carboxynonadecanoyl-gGlu-2xOEG" or "19-carboxynonadecanoyl-gGlu-OEG-OEG", where OEG represents the shorthand for the group -NH(CH2)20(CH2)20CH2CO- (i.e., 2-[2-(2-aminoethoxy)ethoxy]acetyl), and gGlu is the shorthand representation for the amino acid gamma glutamic acid in the L configuration. Alternatively, the acyl moieties can be named according to IUPAC nomenclature (OpenEye, IUPAC format). According to this nomenclature, the above acyl moieties of the present application are referred to as the following name: "[2-[2-[2-[2-[2-[2-[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butyryl]-amino]- ethoxy]-ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]" or "[2-(2-[2-(2-[2-(2-[4-(19- carboxynonadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetyl-amino)ethoxy]ethoxy)acetyl]".

[0180] For example, the insulin of Example 6 of the application (having the sequence / structure given below) is referred to as "B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin," "B29K(Nε-eicosanedioyl-γGlu-5xOEG), desB30 human insulin," or "B29K(Nε-eicosanedioyl-γGlu-5xOEG), desB30 human insulin" to indicate that the amino acid K at position B29 in human insulin has been modified by acylation of the epsilon nitrogen (referred to as Nε or (N(ε)) of the lysine residue at B29 with the residue eicosanedioyl-γGlu-2xOEG, and that the amino acid T at position B30 in human insulin has been deleted. For another example, the insulin of Comparative Example 5 (having the sequence / structure given below) is referred to as "A14E, B16H, B25H, B29K(Nε-eicosanedioyl-γGlu-2xOEG), desB30 human insulin" or "A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-2xOEG), desB30 human insulin" to indicate that the amino acid Y at position A14 in human insulin has been mutated to E, the amino acid Y at position B16 in human insulin has been mutated to H, the amino acid F at position B25 in human insulin has been mutated to H, the amino acid K at position B29 in human insulin has been modified by acylation of the epsilon nitrogen (referred to as Nε) of the lysine residue at B29 with the residue eicosanedioyl-γGlu-2xOEG, and that the amino acid T at position B30 in human insulin has been deleted.

[0181]

[0182] "NxPEG" herein means -NH(CH2CH2O)nCH2CO- where n is an integer. For example, "12xPEG" means the group -NH(CH2CH2O)12CH2CO-. n "NxPEG" herein means -NH(CH2CH2O)nCH2CO- where n is an integer. For example, "12xPEG" means the group -NH(CH2CH2O)12CH2CO-. 12 "NxPEG" herein means -NH(CH2CH2O)nCH2CO- where n is an integer. For example, "12xPEG" means the group -NH(CH2CH2O)12CH2CO-.

[0183] Insulin is a polypeptide hormone secreted by the β-cells in the pancreas, consisting of two polypeptide chains, A and B, which are connected by two interchain disulfide bonds. In addition, the A chain is characterized by having an intrachain disulfide bond.

[0184] There are three main methods for making human insulin in microorganisms. Two involve E. coli, one by expressing a fusion protein in the cytoplasm (Frank et al. (1981) in Peptides: Proceedings of the 7th American Peptide Chemistry Symposium (Rich & Gross, eds.), Pierce Chemical Co., Rockford, III. pp. 729-739), and the other using a signal peptide to enable secretion into the periplasmic space (Chan et al. (1981) PNAS 78:5401-5404). The third method is to use S. cerevisiae to secrete the insulin precursor into the culture medium (Thim et al. (1986) PNAS 83:6766-6770). The prior art discloses many methods of expressing insulin precursors in E. coli or S. cerevisiae, see for example US Patent No. 5,962,267, WO 95 / 16708, EP 0055945, EP 0163529, EP 0347845 and EP 0741188.

[0185] Construction, expression, processing and purification of the carrier of the insulin analogue can be performed using techniques well known to those skilled in the art. The insulin analogue can for example be prepared by expressing a DNA sequence encoding the insulin analogue of interest in a suitable host cell by well known techniques as disclosed in US Patent No. 6500645. The insulin analogue can for example also be prepared by the methods reported in Glendorf T, AR, Nishimura E, Pettersson I, & Kjeldsen T: Importance of the Solvent-Exposed Residues of the Insulin B Chain α-Helix for Receptor Binding; Biochemistry 2008 47 4743-4751. In this publication, mutations were introduced into the insulin-encoding vector using overlap extension PCR. The insulin analogue was expressed as a proinsulin-like fusion protein with an Ala-Ala-Lys small C-peptide in the S. cerevisiae strain MT663. Using A. lyticus endoprotease, the single-chain precursor was enzymatically converted to the two-chain desB30 analogue.

[0186] The isolated insulin analogs can be acylated at the desired position by acylation methods known in the art, examples of such insulin analogs have been described in e.g. Chinese patent applications published as CN1029977C, CN1043719A and CN1148984A.

[0187] The nucleic acid sequences encoding the respective insulin analog polypeptides can be prepared synthetically by established standard methods, e.g. by the methods described in Beaucage et al. (1981) Tetrahedron Letters 22: 1859-1869, or by the methods described in Matthes et al. (1984) EMBO Journal 3: 801-805.

[0188] The application is further illustrated by the following examples. It is to be understood that these examples do not limit the scope of the application.

[0189] Examples

[0190] Abbreviations

[0191] cAMP is cyclic adenosine monophosphate;

[0192] BHK is baby hamster kidney cell;

[0193] DNA is deoxyribonucleic acid;

[0194] Na2HPO4 is sodium phosphate monobasic;

[0195] NaOH is sodium hydroxide;

[0196] OEG is the amino acid residue -NH(CH2)2O(CH2)2OCH2CO-;

[0197] OSu is the succinimidyl-1-yl oxy-2,5-dioxo-pyrrolidin-1-yl oxy group;

[0198] OtBu is the oxy-tert-butyl group;

[0199] HCl is hydrogen chloride;

[0200] yGlu or gGlu is the gamma L-glutamyl group;

[0201] NHS is N-hydroxysuccinimide;

[0202] DCC is dicyclohexyl carbodiimide;

[0203] AEEA is 2-(2-(2-aminoethoxy)ethoxy)acetic acid;

[0204] OH is hydroxide;

[0205] Gly is glycine;

[0206] Arg is arginine;

[0207] TFA is trifluoroacetic acid;

[0208] HbA1c is glycated hemoglobin.

[0209] Example 1

[0210] Title compound: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(19-carboxy-nonadecanoylamino)-4(S)- carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl] [Gly8, Arg34] GLP-1 -(7-37) peptide (Compound 1)

[0211]

[0212] 1, N-ε 26 Preparation of N-ε -[2-(2-[2-(2-[2-(2-[4-(19-carboxy-nonadecanoylamino)-4(S)- carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl] [Gly8, Arg34] GLP-1 -(7-37) peptide

[0213] The [Gly8, Arg34] GLP-1 -(7-37) peptide was prepared by general protein recombinant expression methods (see Molecular Cloning: A Laboratory Manual (Fourth Edition), Michael R. Green, Cold Spring Harbor Press, 2012 for specific methods). The [Gly8, Arg34] GLP-1 -(7-37) peptide (5 g, 1.48 mmol) was dissolved in 100 mM Na2HP04 aqueous solution (150 mL) and acetonitrile (100 mL) was added and the pH adjusted to pH 10-12.5 with 1 N NaOH. Tert-butyl eicosanedioyl-γGlu (2xOEG-OSu)-OtBu (1.59 g, 1.63 mmol) was dissolved in acetonitrile (50 mL) and added slowly to the [Gly8, Arg34] GLP-1 -(7-37) peptide solution. The pH was maintained at 10-12.5. After 120 minutes the reaction mixture was added to water (150 mL) and the pH adjusted to 5.0 with 1 N aqueous HC1. The precipitate was isolated by centrifugation and lyophilized. The crude product was added to a mixture of trifluoroacetic acid (60 mL) and dichloromethane (60 ml) and stirred at room temperature for 30 minutes. The mixture was concentrated to approximately 30 ml, poured into ice-cold n-heptane (300 mL), the precipitated product was isolated by filtration and washed twice with n-heptane. After vacuum drying, the product was purified by ion exchange chromatography (Ressource Q, 0.25-1.25% ammonium acetate gradient in 42.5% ethanol, pH 7.5), reversed phase chromatography (acetonitrile, water, TFA), the purified fractions were combined, the pH adjusted to 5.2 with 1 N HC1, the precipitate was isolated and lyophilized to give the title compound.

[0214] LC-MS (electrospray): m / z = 1028.79 [M+4H] 4+

[0215] 2. Preparation of the intermediate tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu

[0216] 2.1 tert-butyl eicosanedioyl-OSu

[0217] Eicosanedioic acid mono-tert-butyl ester (20 g, 50.17 mmol) and NHS (5.77 g, 50.17 mmol) were mixed in dichloromethane (400 mL) under nitrogen atmosphere, triethylamine (13.95 mL) was added and the resulting turbid mixture was stirred at room temperature, then DCC (11.39 g, 55.19 mmol) was added and it was further stirred overnight. Filtration was carried out and the resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, the layers were separated and the upper organic phase was washed with saturated brine, the upper organic phase was dried over anhydrous sodium sulfate, filtration was carried out and the filtrate was concentrated to almost dryness under reduced pressure, dried under vacuum overnight to obtain 24.12 g (97% yield) of tert-butyl eicosanedioyl-OSu.

[0218] LC-MS (Scie x 100 API): m / z = 496.36 (M+1) +

[0219] 2.2 Tert-butyl eicosanedioyl-γGlu-OtBu

[0220] Tert-butyl eicosanedioyl-OSu (24.12 g, 48.66 mmol) was dissolved in dichloromethane (250 mL) and stirred, H-Glu-OtBu (10.88 g, 53.53 mmol), triethylamine (12.49 mL), water (25 mL) were added sequentially and the resulting solution was heated to obtain a clear solution, which was stirred at room temperature for 4 hours. Then 10% aqueous citric acid solution (200 mL) was added, the layers were separated, the lower organic phase was washed with saturated brine, the lower organic phase was dried over anhydrous sodium sulfate after separation, filtration was carried out and the filtrate was concentrated to almost dryness under reduced pressure, dried under vacuum overnight to obtain 27.27 g (96% yield) of tert-butyl eicosanedioyl-γGlu-OtBu.

[0221] LC-MS (Scie x 100 API): m / z = 584.44 (M+1) +

[0222] 2.3 Tert-butyl eicosanedioyl-γGlu(OSu)-OtBu.

[0223] Tert-butyl eicosanedioyl-γGlu-OtBu (27.27 g, 46.71 mmol) was dissolved in dichloromethane (300 mL) under nitrogen, triethylamine (11.99 mL) was added and stirred for 10 minutes, then NHS (5.38 g, 50.17 mmol) was added, followed by DCC (10.60 g, 51.38 mmol). The mixture was stirred at room temperature overnight. The resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, separated, the upper organic phase was washed with saturated brine water, after separation the upper organic phase was dried over anhydrous sodium sulfate, after filtration the filtrate was concentrated to almost dryness under reduced pressure, methyl tert-butyl ether was added, stirred for 30 minutes, suction filtered, and the filter cake was dried under vacuum overnight to obtain 25.76 g (81% yield) of tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu.

[0224] LC-MS (Scie x 100 API): m / z = 681.46 (M+1) +

[0225] 2.4 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu

[0226] Tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu (25.76 g, 37.83 mmol) was dissolved in dichloromethane (250 mL) and stirred, 2xAEEA (11.66 g, 37.83 mmol) was added, followed by triethylamine (9.71 mL), water (25 mL), which was heated to obtain a clear solution, the solution was stirred at room temperature for 4 hours. Then 10% aqueous citric acid solution (200 mL) was added and separated, the lower organic phase was washed with saturated brine water, after separation the lower organic phase was dried over anhydrous sodium sulfate, after filtration the filtrate was concentrated to almost dryness under reduced pressure, and dried under vacuum overnight to obtain 30.75 g (93% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu.

[0227] LC-MS (Scie x 100 API): m / z = 874.59 (M+1) +

[0228] 2.5 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0229] Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu (30.75 g, 35.18 mmol) was dissolved in dichloromethane (300 mL) under nitrogen, triethylamine (9.03 mL) was added and stirred for 10 minutes, then NHS (4.05 g, 35.18 mmol) was added, followed by DCC (7.98 g, 38.70 mmol). The mixture was stirred at room temperature overnight. The resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, the organic phase was separated and washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to almost dryness under reduced pressure, dried in vacuum overnight to give 31.09 g (91% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0230] LC-MS (Scie x 100 API): m / z = 971.61 (M+1) +

[0231] Example 2

[0232] Title compound: N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide (Compound 2)

[0233]

[0234] Title compound: N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutyrylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide

[0235] LC-MS (Electrospray): m / z = 992.52 [M+4H] 4+

[0236] The intermediate tert-butyl eicosanedioyl-γGlu-(OEG-OSu)-OtBu was prepared in a similar procedure as in Example 1, part 2.

[0237] LC-MS (Scie x 100 API): m / z = 826.54 (M+1) +

[0238] Example 3

[0239] Title compound: N-ε26 (19-carboxynonadecanoylamino)-4(S)-carboxybutyryl- [Gly8, Arg34] GLP-1 -(7-37) peptide (Compound 3)

[0240]

[0241] N-ε 26 (19-carboxynonadecanoylamino)-4(S)-carboxybutyryl- [Gly8, Arg34] GLP-1 -(7-37) peptide

[0242] LC-MS (electrospray): m / z = 956.25 [M + 4H] 4+

[0243] The intermediate tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu was prepared in a similar procedure as in Example 1, Part 2.

[0244] LC-MS (Scie x 100 API): m / z = 681.46 (M + 1) +

[0245] Example 4

[0246] The title compound: N-ε 26 (19-carboxynonadecanoylamino)-4(S)-carboxybutyryl- [Arg34] GLP-1 -(7-37) peptide (Compound 4)

[0247]

[0248] N-ε 26 (19-carboxynonadecanoylamino)-4(S)-carboxybutyryl- [Arg34] GLP-1 -(7-37) peptide

[0249] LC-MS (electrospray): m / z = 956.25 [M + 4H] 4+

[0250] The intermediate tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu was prepared in a similar procedure as in Example 1, Part 2.

[0251] LC-MS (Scie x 100 API): m / z = 681.46 (M + 1) +

[0252] Comparative Example 1

[0253] The reference compound liraglutide was prepared according to example 37 of patent CN1232470A.

[0254] Reference Example 2

[0255] The reference compound semaglutide was prepared according to example 4 of patent CN101133082A.

[0256] Reference Example 3

[0257] Title compound: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)- carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1 -(7-37) peptide

[0258]

[0259] N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)- carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1 -(7-37) peptide

[0260] LC-MS (electrospray): m / z = 1021.78 [M+4H] 4+

[0261] Reference Example 4

[0262] Title compound: N-ε 26 -(17-carboxyheptadecanoylamino)-4(S)-carboxybutyryl-[Gly8,Arg34]GLP-1 -(7-37) peptide

[0263]

[0264] N-ε 26 -(17-carboxyheptadecanoylamino)-4(S)-carboxybutyryl-[Gly8,Arg34]GLP-1 -(7-37) peptide

[0265] LC-MS (electrospray): m / z = 949.24 [M+4H] 4+

[0266] The intermediate tert-butyl octadecandioyl-γGlu-(OSu)-OtBu was prepared in a similar procedure as described in Example 1, part 2.

[0267] LC-MS (Scie x 100 API): m / z = 653.43 (M+1) +

[0268] Example 5: Pharmacodynamic study in db / db mice

[0269] The aim of this study was to demonstrate the regulatory effect of the GLP-1 derivative of the application on hyperglycemia (BG) in the context of diabetes.

[0270] The title compounds of Examples 1-4 and Comparative Examples 1-4 (also called GLP-1 derivatives) were tested in a single-dose study on obese type 2 diabetic (T2DM) mouse model (db / db mice). The GLP-1 derivatives were tested for their hypoglycemic pharmacodynamic effect at different doses of 100 μg / kg.

[0271] 8-9 week old male db / db (BKS / Lepr) mice were housed in a barrier environment in cages of appropriate size with free access to standard chow and purified water, and the environmental conditions were controlled at a relative humidity of 40-60% and a temperature of 22-24°C. After an acclimatization period of 1-2 weeks, the mice were used for the experiment.

[0272] The basal blood glucose was assessed at approximately 9:30 am on the day of the experiment before the start of the experiment, and the mice were weighed. The mice were assigned to the vehicle group or the treatment group according to the random blood glucose and body weight, and were treated as follows: subcutaneous injection of vehicle, or subcutaneous injection of GLP-1 derivative 100 μg / kg, wherein the vehicle contained: propylene glycol 14 mg / ml, phenol 5.5 mg / ml, disodium hydrogen phosphate 1.133 mg / ml, and the pH of the vehicle was 8.12.

[0273] The GLP-1 derivative was dissolved in the vehicle to a dosing concentration of 20 μg / ml, and the dosing volume was 5 ml / kg (i.e. 50 μl / 10 g body weight). The GLP-1 derivative was administered once by subcutaneous injection on the nape of the neck. The corresponding GLP-1 derivative was administered at approximately 10:30 am (time 0), and the animals were allowed to eat and drink freely during the dosing period, and the blood glucose of the mice was assessed at 2, 4, 6, 8, 10, 12, 24, 48 and 72 hours after dosing. The tail of the mouse was cleaned with an alcohol cotton ball, and blood drops were collected from the tail using a disposable blood collection needle, and were measured using a blood glucose meter and the accompanying test paper (Roche). The food intake and the body weight of each mouse were measured at 24, 48 and 72 h after dosing.

[0274] The blood glucose percentage at each monitoring point after administration is compared with the baseline blood glucose before administration, and the blood glucose percentage-time dose response curve is plotted for each single dose of GLP-1 derivative. In order to quantitatively illustrate the effect of GLP-1 derivative on blood glucose, the area under the curve (AUC) of blood glucose percentage-time from 0 to 72 hours is calculated for each individual dose response curve. 0-72h ) wherein AUC is the area under the curve of time-blood glucose percentage, and the smaller the AUC value, the better the hypoglycemic effect and the better the drug efficacy.

[0275] Figures 1a-4b show that the GLP-1 derivatives of the present application have unexpectedly increased drug efficacy, for example, the hypoglycemic effect of the title compound of Examples 1-4 on db / db mice is significantly better than that of Liraglutide, and the compounds of Comparative Examples 3-4. In particular, the hypoglycemic effect of the compound of Example 2 of the present application is better than that of Semaglutide. In addition, the effective action time of the GLP-1 derivatives of the present application, for example, the compounds of Examples 1-4, in db / db mice is significantly prolonged compared with Liraglutide and the compounds of Comparative Examples 3-4, and in particular, the hypoglycemic effective action time of the compound of Example 2 in db / db mice is longer than that of Semaglutide.

[0276] Example 6

[0277] B29K(N(ε)-eicosadioyl-γGlu-5xOEG), desB30 human insulin (Compound 5)

[0278]

[0279] 1. Synthesis of des(B30) human insulin

[0280] des(B30) human insulin was prepared according to the method described in Example 101 of Chinese patent CN1056618C.

[0281] 2. Preparation of target insulin

[0282] Dissolve desB30 human insulin (5 g, 0.876 mmol) in 100 mM Na2HP04in water (150 mL) and add acetonitrile (100 mL) and adjust the pH to pH 10-12.5 with 1 N NaOH. Dissolve t-butyl eicosanedioyl-γGlu-(5xOEG-OSu)-OtBu (1.36 g, 0.964 mmol) in acetonitrile (50 mL) and slowly add to the insulin solution. Maintain the pH at 10-12.5. After 120 minutes, add the reaction mixture to water (150 mL) and adjust the pH to 5.0 with 1 N aqueous HC1. Isolate the precipitate by centrifugation and lyophilize. Add the crude product to a mixture of trifluoroacetic acid (60 mL) and dichloromethane (60 mL) and stir at room temperature for 30 minutes. Concentrate the mixture to about 30 mL, pour into ice-cold n-heptane (300 mL), isolate the precipitated product by filtration and wash twice with n-heptane. After drying in vacuo, purify by ion exchange chromatography (Ressource Q, 0.25-1.25% ammonium acetate gradient in 42.5% ethanol, pH 7.5), reverse phase chromatography (acetonitrile, water, TFA), combine the purified fractions, adjust the pH to 5.2 with 1 N HC1 and isolate the precipitate, lyophilize to give the title compound Compound 5.

[0283] LC-MS (electrospray): m / z = 1377.53 [M+5H] 5+

[0284] 3. Preparation of the intermediate t-butyl eicosanedioyl-γGlu-(5xOEG-OSu)-OtBu

[0285] 3.1 t-butyl eicosanedioyl-OSu

[0286] Mix eicosanedioic acid mono-t-butyl ester (20 g, 50.17 mmol) and NHS (5.77 g, 50.17 mmol) in dichloromethane under nitrogen protection, add triethylamine (13.95 mL), stir the resulting turbid mixture at room temperature, then add DCC (11.39 g, 55.19 mmol) and further stir overnight. Filter, concentrate the resulting filtrate to almost dryness, mix the residue with cold water and ethyl acetate, stir for 20 minutes, separate the upper organic phase, wash with saturated brine, dry the upper organic phase after separation with anhydrous sodium sulfate, filter, concentrate the filtrate to almost dryness under reduced pressure, dry in vacuo overnight to give 24.12 g (97% yield) of t-butyl eicosanedioyl-OSu.

[0287] LC-MS (Scie x 100 API): m / z = 496.36 (M+1) +

[0288] 3.2 Tert-butyl eicosanedioyl-γGlu-OtBu

[0289] Tert-butyl eicosanedioyl-OSu (24.12 g, 48.66 mmol) was dissolved in dichloromethane (250 mL) and stirred, H-Glu-OtBu (10.88 g, 53.53 mmol), triethylamine (12.49 mL), water were added successively to give a clear solution, which was stirred at room temperature for 4 hours. Then 10% aqueous citric acid solution (200 mL) was added, the mixture was partitioned, the lower organic phase was washed with saturated brine, the lower organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to almost dryness under reduced pressure, and dried in vacuum overnight. Tert-butyl eicosanedioyl-γGlu-OtBu (27.27 g, 96% yield) was obtained.

[0290] LC-MS (Scie x 100 API): m / z = 584.44 (M+1) +

[0291] 3.3 Tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu.

[0292] Tert-butyl eicosanedioyl-γGlu-OtBu (27.27 g, 46.71 mmol) was dissolved in dichloromethane (300 mL) under nitrogen protection, triethylamine (11.99 mL) was added successively and stirred for 10 minutes, then NHS (5.38 g, 50.17 mmol) was added, followed by DCC (10.60 g, 51.38 mmol). The mixture was stirred at room temperature overnight. Filtration was performed, and the obtained filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, partitioned, the upper organic phase was washed with saturated brine, the upper organic phase was dried over anhydrous sodium sulfate after partitioning, filtered, and the filtrate was concentrated to almost dryness under reduced pressure, then methyl tert-butyl ether was added, stirred for 30 minutes, suction filtered, and the filter cake was dried in vacuum overnight to obtain tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu (25.76 g, 81% yield).

[0293] LC-MS (Scie x 100 API): m / z = 681.46 (M+1) +

[0294] 3.4 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu

[0295] Tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu (25.76 g, 37.83 mmol) was dissolved in dichloromethane (250 mL) and stirred, 2x AEEA (11.66 g, 37.83 mmol) was added followed by triethylamine (9.71 mL), water (25 mL) and the mixture was heated to give a clear solution. The solution was stirred at room temperature for 4 hours. Then 10% aqueous citric acid (200 mL) was added and the mixture was partitioned. The lower organic phase was washed with saturated brine, partitioned and the lower organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to near dryness under reduced pressure and dried under vacuum overnight. This gave 30.75 g (93% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu.

[0296] LC-MS (Sciex 100 API): m / z = 874.59 (M+1) +

[0297] 3.5 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0298] Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu (30.75 g, 35.18 mmol) was dissolved in dichloromethane (300 mL) and stirred under nitrogen. Triethylamine (9.03 mL) was added and stirred for 10 minutes. NHS (4.05 g, 35.18 mmol) was added followed by DCC (7.98 g, 38.70 mmol). The mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was concentrated to near dryness. The residue was mixed with cold water and ethyl acetate and stirred for 20 minutes. The mixture was partitioned and the upper organic phase was washed with saturated brine, partitioned and the upper organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to near dryness under reduced pressure and dried under vacuum overnight. This gave 31.09 g (91% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0299] LC-MS (Sciex 100 API): m / z = 971.61 (M+1) +

[0300] 3.6 Tert-butyl eicosanedioyl-γGlu-(5xOEG-OH)-OtBu

[0301] Tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu (31.09 g, 32.01 mmol) was dissolved in dichloromethane (350 mL) and stirred, 3x AEEA (14.52 g, 32.01 mmol) was added followed by triethylamine (8.90 mL), water (25 mL) and the mixture was heated to give a clear solution which was stirred at room temperature for 4 hours. A 10% aqueous solution of citric acid (200 mL) was then added and the mixture partitioned, the lower organic phase was washed with saturated brine and the lower organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to near dryness under reduced pressure and dried under vacuum overnight. This gave 38.99 g (93% yield) of tert-butyl eicosanedioyl-γGlu-(5xOEG-OH)-OtBu.

[0302] LC-MS (Scie x 100 API): m / z = 1309.81 (M+1)

[0303] 3.7 Tert-butyl eicosanedioyl-γGlu-(5xOEG-OSu)-OtBu

[0304] Tert-butyl eicosanedioyl-γGlu-(5xOEG-OH)-OtBu (38.99 g, 29.77 mmol) was dissolved in dichloromethane (400 mL) and stirred under nitrogen, triethylamine (8.28 mL) was added and stirred for 10 minutes, followed by the addition of NHS (3.43 g, 29.77 mmol) and then DCC (6.76 g, 32.75 mmol). The mixture was stirred at room temperature overnight. The mixture was filtered and the resulting filtrate was concentrated to near dryness, the residue was mixed with cold water and ethyl acetate and stirred for 20 minutes, the mixture was partitioned and the upper organic phase was washed with saturated brine, the upper organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to near dryness under reduced pressure and dried under vacuum overnight to give 38.11 g (91% yield) of tert-butyl eicosanedioyl-γGlu-(5xOEG-OSu)-OtBu.

[0305] LC-MS (Scie x 100 API): m / z = 1406.83 (M+1) +

[0306] Example 7:

[0307] B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin (Compound 6)

[0308]

[0309] Compound 6 was prepared in a similar procedure to Example 6, part 2.

[0310] LC-MS (electrospray): m / z = 1406.28 [M+5H] 5+

[0311] The intermediate tert-butyl eicosanedioyl-γGlu-(6xOEG-OSu)-OtBu was prepared in a similar procedure as in Example 6, part 3.

[0312] LC-MS (Scie x 100 API): m / z = 1551.90 (M+1) +

[0313] Example 8:

[0314] B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin (Compound 7)

[0315]

[0316] Compound 7 was prepared in a similar procedure as in Example 6, part 2.

[0317] LC-MS (electrospray): m / z = 1464.30 [M+5H] 5+

[0318] The intermediate tert-butyl eicosanedioyl-γGlu-(8xOEG-OSu)-OtBu was prepared in a similar procedure as in Example 6, part 3.

[0319] LC-MS (Scie x 100 API): m / z = 1814.02 (M+1) +

[0320] Example 9:

[0321] B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin (Compound 8)

[0322]

[0323] Compound 8 was prepared in a similar procedure as in Example 6, part 2.

[0324] LC-MS (electrospray): m / z = 1411.88 [M+5H] 5+

[0325] The intermediate tert-butyl docosanedioyl-γGlu-(6xOEG-OSu)-OtBu was prepared in a similar procedure as in Example 6, part 3.

[0326] LC-MS (Scie x 100 API): m / z = 1579.94 (M+1)+

[0327] Example 10:

[0328] B29K(N(ε)-behenoyl-γGlu-8xOEG), desB30 human insulin (Compound 9)

[0329]

[0330] Compound 9 was prepared in a similar procedure as in Example 6, Part 2.

[0331] LC-MS (electrospray): m / z = 1469.91 [M+5H] 5+

[0332] Preparation of the intermediate tert-butyl behenoyl-γGlu-(8xOEG-OSu)-OtBu was carried out in a similar procedure as in Example 6, Part 3.

[0333] LC-MS (Scie x 100 API): m / z = 1870.08 (M+1) +

[0334] Example 11:

[0335] The title compound: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide (Compound 10)

[0336]

[0337] The title compound: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34] GLP-1 -(7-37) peptide

[0338] LC-MS (electrospray): m / z = 1035.80 [M+4H] 4+

[0339] The intermediate tert-butyl behenoyl-γGlu-(2xOEG-OSu)-OtBu was prepared in a similar procedure as in Example 1, Part 2.

[0340] LC-MS (Scie x 100 API): m / z = 999.64 (M+1) +

[0341] Example 12: In vitro potency or activity

[0342] The purpose of this example is to test the in vitro potency or activity of the GLP-1 derivative of the present application

[0343] Recover GLP-1R expressing cells, seed the cells into 25 mL cell culture flask using ham’s-F12 medium, incubate overnight at 37℃, 5% CO2. On the day of experiment, prepare the title compound of Example 11 of the present application (Compound 10) and liraglutide to 150 μg / mL respectively, then gradient dilute the samples to 750 ng / ml, 150 ng / ml, 30 ng / ml, 6 ng / ml, 1.2 ng / ml, 0.24 ng / ml, 0.048 ng / ml, 0.0096 ng / ml and 0.00192 ng / ml. Adjust the cell concentration to 1 x 10 5 50

[0344] Table 1: In vitro potency

[0345] Test subject EC 50 (nM) liraglutide 0.439 Compound 10 0.677

[0346] From the experimental results, it can be seen that the GLP-1 derivative of the present application has satisfactory in vitro potency, and its in vitro activity is close to that of liraglutide, which confirms that it has GLP-1 receptor agonistic activity.

[0347] Example 13: Pharmacodynamic experiment in high-fat diet-induced obese C57BL mice

[0348] The purpose of this study is to confirm the blood glucose regulating effect and weight loss effect of the GLP-1 derivative of the present application in high-fat diet-induced obese C57BL mice.

[0349] ​​C57BL mice (half male and half female) aged 5 weeks and weighing 17-22 g were housed in a barrier environment in appropriate-sized cages (3-5 mice / cage) and given a high-fat diet. The mice in the high-fat diet-induced group were allowed free access to high-fat feed and purified water, and the mice in the normal control group were allowed free access to standard feed and purified water. The environmental conditions were controlled at a relative humidity of 40-60% and a temperature of 22-24°C, and the mice were raised for 10 weeks. Mice whose body weight exceeded that of the normal control mice by 30-50% were selected for efficacy evaluation.

[0350] On the day of the experiment, the basal blood glucose was assessed at time -1 / 1 h (9:30 am), and the mice were weighed. The mice in the high-fat diet-induced group were matched and assigned to the vehicle group (i.e., the model control group) or the treatment group according to the random blood glucose and body weight, and were treated by subcutaneous injection of the vehicle, or subcutaneous injection of the control compound semaglutide 100 μg / kg, or subcutaneous injection of the title compound of Example 11 of the present application at 100 μg / kg and 300 μg / kg. The vehicle contained 14 mg / ml of propylene glycol, 5.5 mg / ml of phenol, and 1.133 mg / ml of disodium hydrogen phosphate, and had a pH of 7.4.

[0351] The mice were administered the GLP-1 derivative once (5 μl / g of body weight) subcutaneously on the back of the neck. The GLP-1 derivative was administered at about 10:30 am (time 0), and the blood glucose of the mice was assessed at 3, 6, 24, 48, and 72 hours after administration. At the same time, the body weight of the mice was monitored every day.

[0352] The Δ blood glucose-time curve was plotted for each single dose of the GLP-1 derivative. Δ refers to the actual blood glucose at a given time minus the baseline, where the baseline is the blood glucose at time 0. Therefore, in these curves, y = 0 represents the baseline. For each individual dose response curve, the area difference under the blood glucose-time curve (ΔAUC) from 0 to the end of the monitoring was calculated. The smaller the ΔAUC value, the better the effect of lowering blood glucose and the better the efficacy.

[0353] An intraperitoneal glucose tolerance test (ipGTT) was performed 48 hours after the first administration, and the procedure was as follows: blood was collected from the tip of the tail to determine the fasting blood glucose (0 min), after which a glucose solution (200 mg / ml, 10 ml / kg) was administered intraperitoneally, and the blood glucose was then determined at 30 min, 60 min, and 120 min after the glucose load.

[0354] The tail of the mouse was cleaned with an alcohol cotton ball, and blood droplets were collected from the tail using a disposable blood collection needle. The blood glucose was determined using a blood glucose meter (Roche) and the accompanying test paper.

[0355] For each single dose of GLP-1 derivative, a dose-response curve of blood glucose versus time, a dose-response curve of daily body weight change versus time are plotted. In order to more intuitively and quantitatively illustrate the effect of the GLP-1 derivative of the present application on blood glucose, for each individual dose-response curve, the relative blood glucose-time area under the curve difference (ΔAUC) from 0 to the monitoring endpoint is calculated. The smaller the ΔAUC value, the better the hypoglycemic effect and the better the drug efficacy.

[0356] Figures 5a-6b show that the GLP-1 derivative of the present application has unexpectedly increased drug efficacy, for example, the hypoglycemic effect of compound 10 of Example 11 on high-fat diet-induced obese C57BL mice is not significantly different from that of the marketed control compound semaglutide at the same dose, and even from the quantitative figures 5b and 6b, it can be seen that the hypoglycemic effect of the GLP-1 derivative of the present application is slightly better than that of semaglutide. Especially at 72 hours after drug administration, the average blood glucose of the compound 10 group at the same dose is lower than that of the semaglutide group at the same dose. In addition, the hypoglycemic effect of the GLP-1 derivative of the present application has a dose-dependent effect, and as the dose of the GLP-1 derivative of the present application increases, the hypoglycemic effect also significantly improves.

[0357] Figures 6a-6b show that in the ipGTT experiment, compound 10 of Example 11 has a significant inhibitory effect on blood glucose 48 hours after the first administration to high-fat diet-induced obese C57BL mice, and the hypoglycemic effect is slightly better than that of semaglutide at the same dose.

[0358] Figure 5c shows that the GLP-1 derivative of the present application, for example, compound 10 of Example 11, has excellent weight loss effect, and the weight loss effect is better than that of semaglutide.

[0359] Example 14: Pharmacodynamic study in type II diabetic db / db mice

[0360] The purpose of this study is to confirm the blood glucose regulating effect of the GLP-1 derivative of the present application in diabetic conditions.

[0361] The blood glucose lowering effect of the title compound of Example 11 and the control compound liraglutide was tested at different doses of 0.3, 1, 3, 10, 30 and 100 nmol / kg on db / db mice, and the ED50 was calculated. 50 .

[0362] 8-9 week old male db / db (BKS / Lepr) mice were housed in a barrier environment in appropriate size cages with free access to standard chow and purified water, and the environmental conditions were controlled at a relative humidity of 40%-60% and a temperature of 22-24°C. After an adaptation period of 1-2 weeks, the mice were used for experiments.

[0363] On the day of the experiment, basal blood glucose was assessed at 9:00 am and the mice were weighed. Diabetic mice were assigned to the vehicle or treatment groups according to random blood glucose and body weight and treated as follows: subcutaneous injection of vehicle, or subcutaneous injection of the compound of Example 11 or the control compound liraglutide 0.3, 1, 3, 10, 30 and 100 nmol / kg, wherein the vehicle comprises: propylene glycol 14 mg / ml, phenol 5.5 mg / ml, disodium hydrogen phosphate 1.133 mg / ml, the pH of the vehicle is 7.4.

[0364] The administration was performed by subcutaneous injection (50 μl / 10 g of body weight) in the nape of the neck. The compound of Example 11 was administered at approximately 10:00 am (time 0) and the blood glucose of the mice was assessed at 1, 2, 3, 6, 12, 24, 48 and 72 hours after administration.

[0365] The tail of the mouse was cleaned with an alcohol swab and a drop of blood was collected from the tail using a disposable lancet and measured with a blood glucose meter (Roche) and the appropriate test paper.

[0366] A dose-response curve of Δ blood glucose versus time was plotted for each single dose of GLP-1 derivative. Δ refers to the actual blood glucose at a given time minus the baseline, where the baseline is the blood glucose at time 0. To illustrate the effect of the GLP-1 derivative on blood glucose, for each individual dose-response curve, the area under the curve of Δ blood glucose from 0 to 72 hours, ΔAUC, was calculated and the effective dose 50% (ED 50 , the dose of GLP-1 derivative that produces half the response between baseline and maximum effect) was calculated. The ED 50 values obtained are shown in Table 2 below.

[0367] Table 2: ED 50 values for the effect on blood glucose in db / db mice

[0368] Sample name ED 50 (nmol / kg) liraglutide 9.68 compound 1 8.42

[0369] From the results of the test, it can be seen that the compound 10 of the present application has a significantly better in vivo hypoglycemic effect than liraglutide.

[0370] Example 15 Pharmacodynamic study in type II diabetic db / db mice

[0371] The aim of this study was to demonstrate the control of blood glucose, food intake and water intake by the GLP-1 derivative of the present application.

[0372] The title compound of Example 2 and the control compound semaglutide were tested in a single dose study on type II diabetic db / db mice.

[0373] 8-9 week old male db / db (BKS / Lepr) mice were housed in a barrier environment in appropriate size cages with free access to standard chow and purified water. The environmental conditions were controlled at a relative humidity of 40-60% and a temperature of 22-24°C. After an acclimation period of 1-2 weeks, the mice were used for experiments.

[0374] The basal blood glucose was assessed at approximately 9:00 am on the day of the experiment and the mice were weighed. The diabetic mice were assigned to the vehicle or treatment groups according to the random blood glucose and body weight and treated with either a subcutaneous injection of vehicle or a subcutaneous injection of the compound of Example 2 or the control compound semaglutide 100 μg / kg, wherein the vehicle contained propylene glycol 14 mg / ml, phenol 5.5 mg / ml, and sodium phosphate dibasic 1.133 mg / ml, pH 7.4.

[0375] The GLP-1 derivative was dissolved in the vehicle to a dosing concentration of 20 μg / ml and administered subcutaneously (50 μl / 10 g body weight) in a single subcutaneous injection in the nape of the neck. The compound of Example 2 was administered at approximately 10:00 am (time 0) and the blood glucose of the mice was assessed at 1, 2, 3, 6, 12, 24, 48, and 72 hours after administration. The tail of the mice was cleaned with an alcohol swab and a drop of blood was collected from the tail using a disposable lancet and measured using a blood glucose meter (Roche) and the accompanying test strips. At the same time, the food intake and water intake of the mice were measured daily.

[0376] For each single dose of GLP-1 derivative, a dose response curve of blood glucose versus time, a dose response curve of food intake versus time, and a dose response curve of water intake versus time were plotted. To illustrate the effect of the GLP-1 derivative of the application on blood glucose, for each individual dose response curve, the area under the curve of blood glucose versus time from 0 to the end of the monitoring was calculated (ΔAUC). The smaller the ΔAUC value, the better the effect on lowering blood glucose and the better the efficacy of the drug.

[0377] Figures 7a-7d show that the GLP-1 derivative of the application has an unexpectedly increased effect on lowering blood glucose, an increased inhibitory effect on food intake, and an increased inhibitory effect on water intake after administration. This further demonstrates that the title compound of Example 2 has a better effect on lowering blood glucose in db / db mice than semaglutide at the same dose after administration. In addition, the title compound of Example 2 can effectively control food intake and water intake, and has a better effect than semaglutide, suggesting that the GLP-1 derivative of the application has a better effect on weight loss.

[0378] Example 16 Long-term pharmacodynamic study in type II diabetic db / db mice

[0379] The purpose of the present study is to confirm the long-term hypoglycemic effect, weight loss effect, and diet control effect of the GLP-1 derivative of the present application on db / db mice of type II diabetes.

[0380] The GLP-1 derivative of Example 11 and the control compound semaglutide were tested on db / db mice of type II diabetes. The GLP-1 derivative was administered to the mice at different doses of 100 and 300 μg / kg, and semaglutide was administered to the mice at a dose of 100 μg / kg, and the effect of the GLP-1 derivative and the control compound semaglutide on reducing blood glucose, reducing body weight, reducing food intake, and reducing water intake was determined.

[0381] 8-9 week old male db / db (BKS / Lepr) mice were housed in a barrier environment in appropriate size cages with free access to standard chow and purified water, and the environmental conditions were controlled at a relative humidity of 40-60% and a temperature of 22-24°C. After an adaptation period of 1-2 weeks, the mice were used for experiments.

[0382] The basal blood glucose was evaluated at about 9:00 am on the day before the experiment, and the mice were weighed. The diabetic mice were matched and assigned to the vehicle group or the treatment group according to the random blood glucose and body weight, and were treated by subcutaneous injection of the vehicle, or subcutaneous injection of the GLP-1 derivative at 100 and 300 μg / kg, or subcutaneous injection of the control compound semaglutide at 100 μg / kg. The vehicle contained 14 mg / ml of propylene glycol, 5.5 mg / ml of phenol, and 1.133 mg / ml of disodium hydrogen phosphate, and the pH value of the vehicle was 7.4.

[0383] The GLP-1 derivative was administered by subcutaneous injection (50 μl / 10 g of body weight) at the nape of the neck at about 10:00 am (time 0), and the blood glucose of the mice was evaluated before each administration and 72 hours after the last administration at days 0, 3, 7, 10, 13, 16, 19, 22, 25, and 28. The body weight, food intake, and water intake of the mice were measured every day from day 0 to day 17, and the body weight, food intake, and water intake of the mice were monitored every 3 days after day 17.

[0384] FIGS. 8a-8f show that the GLP-1 derivative of the present application still has unexpectedly increased hypoglycemic effect, improved weight loss effect, and effect of inhibiting food intake and water intake after long-term administration. As shown in FIGS. 8a and 8b, the compound 10 of Example 11 has a better hypoglycemic effect on db / db mice after long-term administration than the same dose of semaglutide. FIGS. 8c-8d show that the GLP-1 derivative of the present application, such as the title compound of Example 11, has a better weight loss effect and effect of inhibiting food intake and water intake than the same dose of semaglutide.

[0385] Example 17 Long-term pharmacodynamic study in type II diabetic Kkay mice

[0386] The purpose of this study is to confirm the glucose-lowering effect of the GLP-1 derivative of the present application in type II diabetic Kkay mice

[0387] The compound 10 of Example 11, the compound 2 of Example 2, and the control compound dulaglutide (also known as dulaglutanide) were tested on type II diabetic Kkay mice. Compound 10 and compound 2 were administered to the mice at different doses of 100 and 300 μg / kg, and dulaglutide was administered at a dose of 600 μg / kg. The glucose-lowering effect and the effect on HbAlc of the GLP-1 derivative of the present application and the control compound dulaglutide were determined.

[0388] Male Kkay mice aged 12-14 weeks were housed in a barrier environment in cages of appropriate size, with free access to standard chow and purified water, and the environmental conditions were controlled at a relative humidity of 40-60% and a temperature of 22-24°C. After an acclimatization period of 1-2 weeks, the mice were used for the experiment.

[0389] The basal blood glucose was assessed at approximately 9:00 a.m. on the day of the experiment, and the mice were weighed. The diabetic mice were assigned to the vehicle group or the treatment group by matching the random blood glucose and body weight, and were treated by subcutaneous injection of the vehicle, or subcutaneous injection of the GLP-1 derivative of the present application at 100 and 300 μg / kg, or subcutaneous injection of the control compound dulaglutide at 600 μg / kg. The vehicle contained: propylene glycol 14 mg / ml, phenol 5.5 mg / ml, sodium phosphate dibasic 1.133 mg / ml, pH 7.4.

[0390] The GLP-1 derivative of the present application, dulaglutide or the vehicle was administered by subcutaneous administration (50 μl / 10 g body weight) at the nape of the neck, at approximately 10:00 a.m. (time 0), once every 2 days, for 16 consecutive administrations. The blood glucose of the mice was assessed at 3 h, 6 h, 1 day and 2 days after the first administration, and the HbAlc was determined 48 h after the last administration by EDTA anticoagulation.

[0391] Figures 9a-9b show that the GLP-1 derivative of the present application has unexpectedly increased glucose-lowering efficacy, and the title compounds of Example 11 and Example 2 have significantly better glucose-lowering effect on Kkay mice than dulaglutide. Figure 9c shows that the GLP-1 derivative of the present application has significantly better effect on reducing HbAlc in type II diabetic Kkay mice than dulaglutide.

[0392] Example 18 Pharmacokinetics

[0393] The purpose of this example is to illustrate the in vivo pharmacokinetic properties of the compounds of the present application.

[0394] Pharmacokinetics in SD rats

[0395] SD rats, 32 in total, 8 in each group (half male and half female), were divided into Compound 10 low-dose group, Compound 10 middle-dose group, and Compound 10 high-dose group, which were respectively administered 15, 90, 540 pg / kg by subcutaneous injection, and Compound 10 intravenous injection group, which was administered 90 pg / kg by intravenous injection. The Compound 10 low, middle, and high-dose groups were respectively sampled at 0 min (before administration), 1, 3, 5, 8, 12, 16, 24, 36, 48, 72, 96, 120 h after administration to determine the blood drug concentration, and the Compound 10 intravenous injection group was sampled at 0 min (before administration), 1 min, 10 min, 1, 3, 5, 8, 12, 24, 48, 72, 96, 120 h after administration to determine the blood drug concentration. The pharmacokinetic parameters C max , T max , T 1 / 2 , AUC 0-t , MRT were calculated by non-compartment model using WinNonLin v6.4 software, and the test results are shown in Table 3.

[0396] Table 3: Pharmacokinetic parameters after subcutaneous injection of Compound 10 in SD rats

[0397]

[0398]

[0399] C max = maximum measured plasma concentration, T max = time corresponding to the maximum measured blood drug concentration, T 1 / 2 = terminal elimination half-life, AUC 0-t = 0-t time-blood glucose concentration area under the time curve, MRT = mean residence time

[0400] Pharmacokinetics in cynomolgus monkeys

[0401] Cynomolgus monkeys, 24 in each group, 6 in each group (half male and half female), were divided into compound 10 low-dose group, compound 10 middle-dose group, compound 10 high-dose group, and were respectively given 10, 60 and 360 μg / kg by subcutaneous injection, and the compound 10 intravenous injection group was given 60 μg / kg of compound 10 by intravenous injection. The compound 10 low-dose, middle-dose and high-dose groups were respectively given blood sampling for determination of blood drug concentration at 0 min before administration, 1, 3, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168 and 240 h after administration, and the compound 10 intravenous injection group was given blood sampling for determination of blood drug concentration at 0 min before administration, 1 min, 10 min, 1, 3, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 240 h after administration. The WinNonLin v6.4 software was used to calculate the pharmacokinetic parameters by non-compartment model, C max , T max , T 1 / 2 , AUC 0-t , MRT, and the test results are shown in Table 4.

[0402] Table 4: Pharmacokinetic parameters after subcutaneous injection of compound 10 in cynomolgus monkeys

[0403]

[0404] From the above experimental results, it can be seen that the GLP-1 derivative compound 10 of the present application has a long half-life, a large AUC 0-t , a long MRT in rats and cynomolgus monkeys. Moreover, the GLP-1 derivative of the present application has a dose-dependent effect, and the drug efficacy is improved with the increase of the dose.

[0405] Example 19

[0406] The purpose of this experiment is to measure the chemical stability of the GLP-1 derivative preparation of the present application.

[0407] GLP-1 derivative preparation

[0408] Compound 10 was dissolved in 5.68 mg / ml sodium phosphate dibasic solution to a final concentration of 8 mg / ml, and according to the amount of each component in the following table, the auxiliary liquid containing propylene glycol and phenol was added in turn, the pH was adjusted to the value in the following table, and the final GLP-1 compound concentration was 2 mg / ml.

[0409] The chemical stability of the preparation in this example can be shown by the change of high molecular weight protein (HMWP) relative to 0 days after storage at 37℃ for 27 days, and also can be represented by the change of the amount of related substances measured after storage at 37℃ for 28 days.

[0410] Determination of high molecular weight protein (HMWP)

[0411] The content of high molecular weight proteins (HMWP) was determined by high performance liquid chromatography (HPLC) on a Waters TSKgel G2000SWXL (7.8*300 mm), 5 μm column at a column temperature of 30 °C and a sample cell temperature of 5 °C using a mobile phase comprising 300 ml isopropanol, 400 ml glacial acetic acid and 300 ml purified water at a flow rate of 0.5 ml / min. The detection wavelength was 276 nm and the injection volume was 25 μl. Table 5 shows the increase in HMWP after 27 days storage at 37 °C compared to day 0.

[0412] Determination of the amount of related substances

[0413] The content of GLP-1 derivative related impurities was determined by high performance liquid chromatography (HPLC) on a Waters Kromasil 100-3.5-C8 (4.6*250 mm) column at a column temperature of 35 °C and a sample cell temperature of 5 °C using an eluent of a mobile phase comprising:

[0414] Phase A comprises 90 mM potassium dihydrogen phosphate and 10% acetonitrile (v / v), pH 2.4

[0415] Phase B is 75% (v / v) acetonitrile.

[0416] Gradient: linear change from 75% / 25% A / B to 55% / 45% A / B in 0-5 min, linear change to 50% / 50% A / B in 5-12 min, linear change to 40% / 60% A / B in 12-42 min, linear change to 10% / 90% A / B in 42-60 min, linear change to 75% / 25% A / B in 60-61 min, isocratic gradient of 85% / 15% A / B in 61-70 min.

[0417] The detection wavelength was 214 nm, the flow rate was 1.0 ml / min and the injection volume was 15 μl. Table 5 shows the increase in related substances after 28 days storage at 37 °C compared to day 0.

[0418] Table 5

[0419]

[0420]

[0421] From the above table it can be concluded that the formulations have a good chemical stability between pH 6.5 and 8.4 and that the chemical stability of the formulations is best between pH 7.0 and 8.0.

[0422] Example 20

[0423] The purpose of this experiment was to measure the chemical stability of GLP-1 derivative formulations of the present application.

[0424] GLP-1 derivative formulations in Tables 6 and 7 were prepared according to the amounts of each component in Tables 6 and 7, respectively, following similar procedures as in Example 19. Changes in HMWP and related substances were measured following similar procedures as in Example 19. Tables 6 and 7 below show the changes in HMWP and related substances for GLP-1 derivative formulations of different formulations.

[0425] Table 6

[0426]

[0427] Table 7

[0428]

[0429]

[0430] From the above tables, it can be seen that the amount of HMWP and the amount of related substances in the above GLP-1 derivative formulations of the present application increased very slowly over time, indicating that the above GLP-1 derivative formulations all have excellent chemical stability.

[0431] Comparative Example 5

[0432] A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-2xOEG), desB30 human insulin (Comparative Compound 5)

[0433]

[0434] 1. Preparation of A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-2xOEG), desB30 human insulin

[0435] A14E, B16H, B25H, desB30 human insulin was prepared by conventional methods for preparing insulin analogs (see Glendorf T, et al., Protein Expr. Purif. 2002, 24: 245-252 for a specific method). AR, Nishimura E, Pettersson I, & Kjeldsen T: Importance of the Solvent-Exposed Residues of the Insulin B Chain alpha-Helix for Receptor Binding; Biochemistry 2008 47 4743-4751). A14E, B16H, B25H, desB30 human insulin (5 g, 0.888 mmol) was dissolved in 100 mM Na2HP04in water (150 mL) and acetonitrile (100 mL) was added and the pH was adjusted to pH 10-12.5 with 1 N NaOH. tert-Butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu (0.948 g, 0.976 mmol) was dissolved in acetonitrile (50 mL) and added slowly to the insulin solution. The pH was maintained at 10-12.5. After 120 minutes the reaction mixture was added to water (150 mL) and the pH was adjusted to 5.0 with 1 N aqueous HC1. The precipitate was isolated by centrifugation and lyophilized. The lyophilized crude product was added to a mixture of trifluoroacetic acid (60 mL) and dichloromethane (60 ml) and stirred at room temperature for 30 minutes. The mixture was concentrated to about 30 ml, poured into ice-cold n-heptane (300 mL) and the precipitated product was isolated by filtration and washed twice with n-heptane. After drying in vacuo the purified fractions were combined, the pH was adjusted to 5.2 with 1 N HC1 and the precipitate was isolated, lyophilized to give control compound 5.

[0436] LC-MS (electrospray): m / z = 1063.6852 [M+6H] 6+

[0437] 2. Preparation of the intermediate tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu: Performed in a similar procedure as in Example 1, part 3.

[0438] 2.1 tert-Butyl eicosanedioyl-OSu

[0439] Eicosanedioic acid mono-tert-butyl ester (20 g, 50.17 mmol) and NHS (5.77 g, 50.17 mmol) were mixed in dichloromethane under nitrogen, triethylamine (13.95 mL) was added and the resulting hazy mixture was stirred at room temperature, then DCC (11.39 g, 55.19 mmol) was added and further stirred overnight. Filtration was performed and the resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, the layers were separated and the upper organic phase was washed with saturated brine, the layers were separated and the upper organic phase was dried over anhydrous sodium sulfate, filtration was performed and the filtrate was concentrated to almost dryness under reduced pressure, dried under vacuum overnight to obtain 24.12 g (97% yield) of tert-butyl eicosanedioyl-OSu.

[0440] LC-MS (Scie x 100 API): m / z = 496.36 (M+1) +

[0441] 2.2 Tert-butyl eicosanedioyl-γGlu-OtBu

[0442] Tert-butyl eicosanedioyl-OSu (24.12 g, 48.66 mmol) was dissolved in dichloromethane (250 mL) and stirred, H-Glu-OtBu (10.88 g, 53.53 mmol), triethylamine (12.49 mL) and water were added sequentially to obtain a clear solution, which was stirred at room temperature for 4 hours. Then 10% aqueous citric acid solution (200 mL) was added, the layers were separated, the lower organic phase was washed with saturated brine, the layers were separated and the lower organic phase was dried over anhydrous sodium sulfate, filtration was performed and the filtrate was concentrated to almost dryness under reduced pressure, dried under vacuum overnight to obtain 27.27 g (96% yield) of tert-butyl eicosanedioyl-γGlu-OtBu.

[0443] LC-MS (Scie x 100 API): m / z = 584.44 (M+1) +

[0444] 2.3 Tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu.

[0445] Tert-butyl eicosanedioyl-γGlu-OtBu (27.27 g, 46.71 mmol) was dissolved in dichloromethane (300 mL) under nitrogen, triethylamine (11.99 mL) was added and stirred for 10 min, then NHS (5.38 g, 50.17 mmol) was added, followed by DCC (10.60 g, 51.38 mmol). The mixture was stirred at room temperature overnight. The resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 min, the organic phase was separated and the upper layer was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to almost dryness under reduced pressure, methyl tert-butyl ether was added, stirred for 30 min, filtered and the filter cake was dried under vacuum overnight to obtain 25.76 g (81% yield) of tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu.

[0446] LC-MS (Scie x 100 API): m / z = 681.46 (M+1) +

[0447] 2.4 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu

[0448] Tert-butyl eicosanedioyl-γGlu-(OSu)-OtBu (25.76 g, 37.83 mmol) was dissolved in dichloromethane (250 mL) and stirred, 2x AEEA (11.66 g, 37.83 mmol), triethylamine (9.71 mL), water (25 mL) were added sequentially to obtain a clear solution, which was stirred at room temperature for 4 h. Then 10% aqueous citric acid solution (200 mL) was added, the mixture was separated and the lower organic phase was washed with saturated brine, the lower organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to almost dryness under reduced pressure, and dried under vacuum overnight to obtain 30.75 g (93% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu.

[0449] LC-MS (Scie x 100 API): m / z = 874.59 (M+1) +

[0450] 2.5 Tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0451] Tert-butyl eicosanedioyl-γGlu-(2xOEG-OH)-OtBu (30.75 g, 35.18 mmol) was dissolved in dichloromethane (300 mL) under nitrogen, triethylamine (9.03 mL) was added and stirred for 10 minutes, then NHS (4.05 g, 35.18 mmol) was added, followed by DCC (7.98 g, 38.70 mmol). The mixture was stirred at room temperature overnight. The resulting filtrate was concentrated to almost dryness, the residue was mixed with cold water and ethyl acetate, stirred for 20 minutes, the organic phase was separated and the upper layer was washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to almost dryness under reduced pressure, dried in vacuum overnight to give 31.09 g (91% yield) of tert-butyl eicosanedioyl-γGlu-(2xOEG-OSu)-OtBu.

[0452] LC-MS (Scie x 100 API): m / z = 971.61 (M+1) +

[0453] Example 21

[0454] A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin (Compound 11)

[0455]

[0456] Compound A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin was prepared in a similar manner as in Part 1 of Comparative Example 5.

[0457] LC-MS (Electrospray): m / z = 1160.3997 [M+6H] 6+

[0458] The intermediate tert-butyl eicosanedioyl-γGlu-(6xOEG-OSu)-OtBu was prepared in a similar manner as in Part 2 of Comparative Example 5.

[0459] LC-MS (Scie x 100 API): m / z = 1551.90 (M+1) +

[0460] Example 22

[0461] A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin (Compound 12)

[0462]

[0463] Compound A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin was prepared in a similar procedure as in Comparative Example 5, Part 1.

[0464] LC-MS (electrospray): m / z = 1165.0674 [M+6H] 6+

[0465] Preparation of the intermediate tert-butyl eicosanedioyl-γGlu-(6xOEG-OSu)-OtBu was performed in a similar procedure as in Comparative Example 5, Part 2.

[0466] LC-MS (Scie x 100 API): m / z = 1579.94 (M+1) +

[0467] Example 23

[0468] A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin (Compound 13)

[0469]

[0470] Compound A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin was prepared in a similar procedure as in Comparative Example 5, Part 1.

[0471] LC-MS (electrospray): m / z = 1305.4716 [M+6H] 6+

[0472] Preparation of the intermediate tert-butyl eicosanedioyl-γGlu-(12xOEG-OSu)-OtBu was performed in a similar procedure as in Comparative Example 5, Part 2.

[0473] LC-MS (Scie x 100 API): m / z = 2423.35 (M+1) +

[0474] Example 24

[0475] A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin (Compound 14)

[0476]

[0477] Compound A14E, B16H, B25H, B29K(N(ε)-behenoyl-γGlu-12xOEG), desB30 human insulin was prepared in a similar procedure as in Comparative Example 5, part 1.

[0478] LC-MS (electrospray): m / z = 1310.1425 [M+6H] 6+

[0479] The preparation of the intermediate tert-butyl behenoyl-γGlu-(12xOEG-OSu)-OtBu was performed in a similar procedure as in Comparative Example 5, part 2.

[0480] LC-MS (Scie x 100 API): m / z = 2451.38 (M+1) +

[0481] Example 25 GLP-1 receptor binding

[0482] The purpose of this example was to test the in vitro receptor binding affinity of the GLP-1 derivatives of the application, and how the presence of albumin potentially influences the binding. Receptor binding is a measure of the affinity of the GLP-1 derivatives for the human GLP-1 receptor.

[0483] The binding affinity of the GLP-1 derivatives of the application and the control compounds to the human GLP-1 receptor was determined by measuring their ability to displace 125 I-GLP-1 from the receptor. To determine the binding of the GLP-1 derivatives to albumin (HSA), the determination was performed with low concentration of albumin (0.005% (w / v)), as well as with high concentration of albumin (2% (w / v)). Changes in the binding affinity IC 50 of the GLP-1 derivatives to albumin indicate binding of the GLP-1 derivatives to albumin, and thereby a potential prolonged pharmacokinetic profile of the GLP-1 derivatives in animal models.

[0484] For receptor binding assays in the presence of low HSA (0.005% (w / v)), 50 μΐ of assay buffer was added to each well of the assay plate. For receptor binding assays in the presence of high HSA (2% (w / v)), 50 μΐ of 8% (w / v) albumin stock was added to each well of the assay plate. Test compounds were prepared in 10 mM Na2HP04, pH 7.3, and reference control GLP-1 (7-37) was prepared in ultrapure water as a 1 mM stock. For the 0.005% HSA condition, all test compounds and reference control were diluted to 2 μΜ in assay buffer, followed by a 4-fold serial dilution, for a total of 10 concentration steps. For the 2% HSA condition, reference control GLP-1 (7-37) was diluted to 2 μΜ, liraglutide to 20 μΜ, Compound 10 and semaglutide to 800 μΜ, followed by a 4-fold serial dilution for all samples, for a total of 10 concentration steps. Twenty-five μΐ of test compound or reference control at the different concentrations was added to the appropriate wells of the assay plate. An aliquot of cell membrane protein was thawed and diluted to its working concentration (40 μg / mL), and 50 μΐ of cell membrane containing solution was added to each well of the assay plate. Incubation was initiated by adding 25 μΐ of a 600 pM solution of [ 125 I]-GLP-1 to each well of the assay plate. The assay plate was incubated for 1 h at room temperature. After incubation, the reaction was harvested onto a GF / C filter plate using a cell harvester, washed 6 times with wash buffer, and dried in a 50 °C drying oven for 1 h. Fifty μΐ of scintillation fluid was added, and the plate was sealed and read using a Microbeta2. IC 50 values were calculated using non-linear regression analysis in GraphPad Prism and reported in nM. Each test compound was repeated a minimum of three times. The reported values are the average of all measurements for each test compound.

[0485] Table 8: GLP-1 receptor binding affinities

[0486]

[0487] “Ratio” refers to [(IC 50 / nM) high HSA] / [(IC 50 / nM) low HSA]

[0488] Generally, binding to the GLP-1 receptor should be as good as possible at low albumin concentrations, which corresponds to low IC 50 values. The IC 50 value at high albumin is a measure of the influence of albumin on the binding of the GLP-1 derivative to the GLP-1 receptor. As is known, GLP-1 derivatives also bind to albumin, which is generally a desired effect, as this will prolong their plasma lifetime. Thus, the IC50 Values are typically higher than IC50 at low albumin 50 Values, corresponding to a reduced binding to the GLP-1 receptor, due to albumin binding competing with GLP-1 receptor binding.

[0489] Thus, the ratio (IC50 (high albumin) / IC50 (low albumin)) can be employed as an indication that the target derivative binds well to albumin (thus can be determined to have a long half-life), and also binds well to the GLP-1 receptor itself (IC50 (high albumin) is high, IC50 (low albumin) is low). 50 Values are typically higher than IC50 at low albumin 50 Values, corresponding to a reduced binding to the GLP-1 receptor, due to albumin binding competing with GLP-1 receptor binding. 50 Values are typically higher than IC50 at low albumin 50 Values, corresponding to a reduced binding to the GLP-1 receptor, due to albumin binding competing with GLP-1 receptor binding.

[0490] As can be seen from the above table, the ratio of the GLP-1 derivatives of the present application is higher than the control compounds semaglutide, liraglutide and GLP-1 (7-37), indicating that the compounds of the present application have a longer half-life, and also bind well to the GLP-1 receptor itself.

[0491] Example 26 Long-term pharmacodynamic study in type II diabetic db / db mice

[0492] A long-term pharmacodynamic study was performed in type II diabetic db / db mice following similar experimental procedures as in Example 16, except that the control compound used was dulaglutide, and the dose of dulaglutide administered was 300 μg / kg. The GLP-1 derivatives were administered subcutaneously (50 μl / 10 g body weight) in the nape of the neck, at approximately 10:00 am (time 0), and on days 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, respectively. The blood glucose of the mice was assessed at 3, 6, 9, 12, 24, 48 and 72 hours after the first administration, and the change in the area under the blood glucose-time curve (ΔAUC) was calculated. Fasting blood glucose was monitored 6 hours after fasting for 48 hours before administration, at 3, 5, and 11 times after administration. The intraperitoneal glucose tolerance test (ipGTT) was performed 48 hours after the first administration, following the procedure: blood was collected from the tip of the tail at the indicated time points to determine fasting blood glucose (0 min), after which a glucose solution (200 mg / ml, 10 ml / kg) was administered intraperitoneally, and blood glucose was determined at 30 min, 60 min and 120 min after the glucose load. The tail of the mouse was cleaned with an alcohol swab, and blood drops were collected from the tail using a disposable lancet, and determined using a blood glucose meter (Roche) and the accompanying test strips. The time-blood glucose curve was plotted, and the area under the time-blood glucose curve (AUC) was calculated.

[0493] Figures 10a-10e show that the GLP-1 derivatives of the present application have unexpectedly increased hypoglycemic effects after long-term administration. As shown in Figures 10a and 10b, the compound 10 of Example 11 has a superior hypoglycemic effect on db / db mice after administration compared to dulaglutide. As shown in Figure 10c, the compound 10 has a superior hypoglycemic effect on db / db mice after long-term administration compared to dulaglutide. As shown in Figures 10d-10e, the GLP-1 derivatives of the present application have a more pronounced inhibitory effect on blood glucose than dulaglutide, and are superior to the hypoglycemic effect of dulaglutide.

[0494] Example 27 Pharmacodynamic experiment in high-fat diet-induced obese C57BL mice

[0495] A pharmacodynamic experiment was performed in high-fat diet-induced obese C57BL mice using similar experimental procedures as in Example 13, except that the control compound used was dulaglutide, and the dose of dulaglutide administered was 300 μg / kg.

[0496] Subcutaneous administration was performed once (5 μl / g body weight) on the nape of the neck, once every 3 days, for a total of 11 times. The GLP-1 derivative was administered at approximately 10:30 am (time 0), and the blood glucose of the mice was evaluated at 3, 6, 9, 12, 24, 48, and 72 hours after administration. At the same time, the body weight and food intake of the mice were monitored every 3 days. At the end of the experiment, the subcutaneous fat, perirenal fat, and perireproductive fat were weighed.

[0497] Figures 11a-11d show that the GLP-1 derivatives of the present application have unexpectedly improved weight loss effects, diet control effects, and lipid-lowering effects.

[0498] Example 28

[0499] B29K(N(ε)-behenoyl-γGlu-12xOEG), desB30 human insulin (Compound 15)

[0500]

[0501] Compound B29K(N(ε)-behenoyl-γGlu-12xOEG), desB30 human insulin was prepared using similar procedures as in Part 2 of Example 6.

[0502] LC-MS (electrospray): m / z = 1585.98 [M+5H] 5+

[0503] The intermediate tert-butyl behenoyl-γGlu-(12xOEG-OSu)-OtBu was prepared using similar procedures as in Part 3 of Example 6.

[0504] LC-MS (Scie x 100 API): m / z = 2451.38 (M+1) +

[0505] Example 29

[0506] A14E, B16H, B25H, B29K(N(ε)-behenoyl-γGlu-18xOEG), desB30 human insulin (Compound 16)

[0507]

[0508] Compound A14E, B16H, B25H, B29K(N(ε)-behenoyl-γGlu-24xOEG), desB30 human insulin was prepared in a similar procedure as in Example 5, Part 1.

[0509] LC-MS (electrospray): m / z = 1247.47 [M+7H] 7+

[0510] The preparation of the intermediate tert-butyl behenoyl-γGlu-(24xOEG-OSu)-OtBu was performed in a similar procedure as in Example 5, Part 2.

[0511] LC-MS (Scie x 100 API): m / z = 3320.83 (M+1) +

[0512] Example 30

[0513] A14E, B16H, B25H, B29K(N(ε)-behenoyl-γGlu-24xOEG), desB30 human insulin (Compound 17)

[0514]

[0515] Compound A14E, B16H, B25H, B29K(N(ε)-behenoyl-γGlu-24xOEG), desB30 human insulin was prepared in a similar procedure as in Example 5, Part 1.

[0516] LC-MS (electrospray): m / z = 873.35 [M+11H] 11+

[0517] The preparation of the intermediate tert-butyl behenoyl-γGlu-(24xOEG-OSu)-OtBu was performed in a similar procedure as in Example 5, Part 2.

[0518] LC-MS (Sciex 100 API): m / z = 4192.27 (M+1) +

[0519] Example 31

[0520] B29K(N(ε)-behenoyl-γGlu-OEG), desB30 human insulin (Compound 18)

[0521]

[0522] Compound B29K(N(ε)-behenoyl-γGlu-OEG), desB30 human insulin was prepared in a similar procedure as in Example 6, Part 2.

[0523] LC-MS (electrospray): m / z = 1266.8122 [M+5H] 5+

[0524] The intermediate tert-butyl behenoyl-γGlu-(OEG-OSu)-OtBu was prepared in a similar procedure as in Example 6, Part 3.

[0525] LC-MS (Sciex 100 API): m / z = 854.57 (M+1) +

[0526] Example 32

[0527] B29K(N(ε)-behenoyl-γGlu-12xPEG), desB30 human insulin (Compound 19)

[0528]

[0529] Compound B29K(N(ε)-behenoyl-γGlu-12xPEG), desB30 human insulin was prepared in a similar procedure as in Example 6, Part 2.

[0530] LC-MS (electrospray): m / z = 1354.8667 [M+5H] 5+

[0531] The intermediate tert-butyl behenoyl-γGlu-(12xPEG-OSu)-OtBu was prepared in a similar procedure as in Example 6, Part 3.

[0532] LC-MS (Sciex 100 API): m / z = 1294.83 (M+1) +

[0533] The present application has been described by way of the above examples, but it should be understood that the above examples are for illustrative and explanatory purposes only, and are not intended to limit the present application to the scope of the described examples. Furthermore, those skilled in the art can understand that the present application is not limited to the above examples, and that various modifications and changes can be made to the present application according to the teachings of the present application, and that these modifications and changes all fall within the scope of the present application claimed. The scope of protection of the present application is defined by the appended claims and their equivalents.

Claims

1. A compound of formula B, or a pharmaceutically acceptable salt, amide or ester thereof: [Acy-(L1) r -(L2) q -G1 (B), wherein G1 is a GLP-1 analogue having Arg at position 34 and Ala or Gly at position 8 corresponding to GLP-1(7-37) (SEQ ID NO: 1), [Acy-(L1) r -(L2) q is a substituent attached to the ε-amino group of the Lys residue at position 26 of said GLP-1 analogue, wherein r is an integer from 1 to 10, and q is 0 or an integer from 1 to 10; Acy is an aliphatic diacid containing 20 - 24 carbon atoms, wherein formally a hydroxyl group has been removed from one of the carboxyl groups of said aliphatic diacid; L1 is an amino acid residue selected from the following: γGlu, αGlu, βAsp, αAsp, γ-D-Glu, α-D-Glu, β-D-Asp or α-D-Asp; L2 is a neutral amino acid residue containing an alkylenediol; Acy, L1, and L2 are linked by an amide bond; and the order in which L1 and L2 appear in formula (B) can be independently interchanged.

2. The compound according to claim 1, wherein, G1 is the peptide [Gly8, Arg34]GLP-1-(7-37) (SEQ ID NO: 2) or [Arg34]GLP-1-(7-37) (SEQ ID NO: 3), preferably the peptide [Gly8, Arg34]GLP-1-(7-37); and / or r is 1, 2, 3, 4, 5 or 6, preferably, r is 1, 2, 3 or 4, preferably, r is 1 or 2, preferably, r is 1; and / or q is 0, 1, 2, 3, 4, 5, 6, 7 or 8, preferably, q is 0, 1, 2, 3 or 4, more preferably, q is 0, 1, or 2; and / or Acy is an aliphatic diacid containing 20-23 carbon atoms, preferably Acy is an aliphatic diacid containing 20, 21, or 22 carbon atoms.

3. The compound according to claim 1 or 2, wherein, L2 is: -HN-(CH2)2-O-(CH2)2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-CH2-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)3-O-CH2-CO-, or -HN-(CH2)4-O-(CH2)4-O-CH2-CO-; preferably L2 is -HN-(CH2)2-O-(CH2)2-O-CH2-CO-; and / or L1 is selected from γGlu or βAsp, preferably L1 is γGlu; and / or Acy is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 19 -CO-, HOOC-(CH2) 20 -CO-, HOOC-(CH2) 21 -CO- or HOOC-(CH2) 22 -CO-, preferably, Acy is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 20 -CO- or HOOC-(CH2) 22 -CO-.

4. The compound according to any one of claims 1 - 3, wherein, In formula (B), Acy, L1, and L2 are sequentially connected by amide bonds, and the C-terminus of L2 is connected to the ε-amino group of the Lys residue at position 26 of the GLP-1 analogue.

5. The compound according to claim 1, said compound being selected from the following compounds: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(19-carboxynonadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(4-[19-Carboxy nonadecanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(2-[2-(2-[4-(21-Carboxy heneicosanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(4-[21-Carboxy heneicosanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(2-[2-(2-[4-(23-Carboxy tricosanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(4-[23-Carboxy tricosanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 -(23-Carboxy tricosanoyl amino)-4(S)-carboxy butyryl-[Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 -(19-Carboxy nonadecanoyl amino)-4(S)-carboxy butyryl-[Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 -(21-Carboxy heneicosanoyl amino)-4(S)-carboxy butyryl-[Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 - [2-(2-[2-(2-[2-(2-[4-(19-Carboxy nonadecanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26-[2-(2-[2-(4-[19-Carboxy nonadecanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-Carboxy heneicosanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[21-Carboxy heneicosanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(23-Carboxy tricosanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[23-Carboxy tricosanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -(23-Carboxy tricosanoyl amino)-4(S)-carboxy butyryl-[Arg34]GLP-1-(7-37) peptide, N-ε 26 -(19-Carboxy nonadecanoyl amino)-4(S)-carboxy butyryl-[Arg34]GLP-1-(7-37) peptide, N-ε 26 -(21-Carboxy heneicosanoyl amino)-4(S)-carboxy butyryl-[Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(20-Carboxy eicosanoyl amino)-4(S)-carboxy butyryl amino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26-[2-(2-[2-(4-[20-Carboxyicosanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(22-Carboxydocosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[22-Carboxydocosanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26 -(20-Carboxyicosanoylamino)-4(S)-carboxybutanoyl-[Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26 -(22-Carboxydocosanoylamino)-4(S)-carboxybutanoyl-[Gly8,Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(20-Carboxyicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[20-Carboxyicosanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(22-Carboxydocosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[22-Carboxydocosanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37) peptide, N-ε 26-(20-Carboxyicosanoylamino)-4(S)-carboxybutanoyl-[Arg34]GLP-1-(7-37) peptide, or N-ε 26 -(22-Carboxydocosanoylamino)-4(S)-carboxybutanoyl-[Arg34]GLP-1-(7-37) peptide; Preferably, the compound is selected from the following compounds: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(19-Carboxynonadecanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(4-[19-Carboxynonadecanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, N-ε 26 -(19-Carboxynonadecanoylamino)-4(S)-carboxybutanoyl-[Gly8, Arg34]GLP-1-(7-37) peptide, N-ε26-(19-Carboxynonadecanoylamino)-4(S)-carboxybutanoyl-[Arg34]GLP-1-(7-37) peptide, N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-Carboxyhenicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide, or N-ε 26 -[2-(2-[2-(4-[21-Carboxyhenicosanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide.

6. A pharmaceutical preparation, which comprises the compound according to any one of claims 1-5 and a pharmaceutically acceptable excipient.

7. The pharmaceutical preparation according to claim 6, wherein the pharmaceutically acceptable excipient is selected from one or more of buffers, preservatives, isotonic agents, stabilizers and chelating agents; preferably, the pharmaceutically acceptable excipient is a buffer, a preservative and an isotonic agent.

8. The pharmaceutical preparation according to any one of claims 6-7, wherein the isotonic agent is selected from one or more of sodium chloride, propylene glycol, mannitol, sorbitol, glycerol, glucose and xylitol, preferably propylene glycol, mannitol or sodium chloride; and / or the preservative is selected from one or more of phenol, m-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, and benzyl alcohol, preferably phenol or m-cresol; and / or the buffer is selected from one or more of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethane, preferably sodium acetate, citrate, sodium dihydrogen phosphate, or disodium hydrogen phosphate.

9. The pharmaceutical preparation according to any one of claims 6-8, wherein The pH of the formulation is from about 6.0 to about 10.0, preferably from about 6.5 to about 10.0, preferably from about 6.5 to about 9.5, preferably from about 6.5 to about 8.5, more preferably from about 7.0 to about 8.5, more preferably from about 7.0 to about 8.1, and further preferably from about 7.3 to about 8.

1.

10. A pharmaceutical preparation comprising the following components: about 0.1-1.2 mM, preferably about 0.2-1 mM, preferably about 0.3-0.7 mM, more preferably about 0.48-0.6 mM of the compound according to any one of claims 1-5; about 10-1500 mM, preferably about 13-800 mM, preferably about 65-400 mM, preferably about 90-240 mM, preferably about 150-250 mM, preferably about 180-200 mM, more preferably about 183-195 mM of an isotonic agent, preferably, the isotonic agent is selected from one or more of propylene glycol, glycerol, mannitol or sodium chloride; about 1-200 mM, preferably about 5-150 mM, preferably about 10-100 mM, preferably about 20-85 mM, preferably about 30-75 mM, preferably about 45-60 mM, more preferably about 50-60 mM of a preservative, preferably, the preservative is selected from one or more of phenol or m-cresol; about 3-35 mM, preferably about 5-20 mM, more preferably about 5-15 mM, more preferably about 7-10 mM of a buffer, the buffer is selected from one or more of sodium acetate, citrate, sodium dihydrogen phosphate or disodium hydrogen phosphate; and the pH of the pharmaceutical preparation is about 6.0 to about 10.0, preferably about 6.5 to about 9.5, preferably about 6.5 to about 8.5, more preferably about 7.0 to about 8.5, more preferably about 7.0 to about 8.1, further preferably about 7.3 to about 8.

1.

11. A pharmaceutical preparation comprising: about 0.3-0.7 mM, more preferably about 0.48-0.6 mM of N-ε 26-[2-(2-[2-(2-[2-(2-[4-(21-carboxyhenicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide or N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide; Propylene glycol at about 180 - 200 mM, more preferably about 183 - 195 mM; Phenol at about 45 - 60 mM, more preferably about 50 - 60 mM; A buffer at about 5 - 15 mM, preferably disodium hydrogen phosphate at about 7 - 10 mM; and The pH of the pharmaceutical preparation is from about 6.5 to about 8.5, more preferably from about 7.0 to about 8.5, and even more preferably from about 7.3 to about 8.

3.

12. A pharmaceutical preparation, comprising: About 0.5 mM of N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyhenicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide or N-ε 26 -[2-(2-[2-(4-[19-carboxynonadecanoylamino]-4(S)-carboxybutanoylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide; About 184 mM of propylene glycol; About 58.5 mM of phenol; About 10 mM of disodium hydrogen phosphate; and The pH of the pharmaceutical preparation is from about 6.5 to about 8.5, more preferably from about 7.0 to about 8.5, more preferably from about 7.0 to about 8.1, and even more preferably from about 7.3 to about 8.

1.

13. A pharmaceutical preparation, comprising: About 2.0 mg / ml of N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyhenicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide or N-ε 26-[2-(2-[2-(4-[19-Carboxy nonadecanoyl amino]-4(S)-carboxy butyryl amino)ethoxy]ethoxy)acetyl][Gly8, Arg34]GLP-1-(7-37) peptide; Propylene glycol at about 14 mg / ml; Phenol at about 5.5 mg / ml; Disodium hydrogen phosphate at about 1.42 mg / ml; and The pH of the pharmaceutical preparation is from about 6.5 to about 8.5, more preferably from about 7.0 to about 8.5, more preferably from about 7.0 to about 8.1, and even more preferably from about 7.3 to about 8.

1.

14. A pharmaceutical composition comprising the compound according to any one of claims 1-5, and acylated insulin. Preferably, the acylated insulin is B29K(N(ε)-docosanedioyl-γGlu-OEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-2xOEG), desB30 human insulin; or B29K(N(ε)-docosanedioyl-γGlu-12xPEG), desB30 human insulin; More preferably, the acylated insulin is the following acylated insulin, the insulin parent of the acylated insulin is a naturally occurring insulin or an insulin analogue, and contains at least one lysine residue. The acyl moiety of the acylated insulin is linked to the amino group of the lysine residue or the N-terminal amino acid residue of the insulin parent. The acyl moiety is as shown in formula (A): III-(II) m -(I) n - (A), Wherein, m is 0 or an integer from 1 to 10, and n is an integer from 5 to 30 (preferably 5 to 20); I is a neutral amino acid residue containing an alkylene glycol; II is an acidic amino acid residue; III is an aliphatic diacid containing 20-24 carbon atoms, wherein formally a hydroxyl group has been removed from one of the carboxyl groups of the aliphatic diacid; III, II, and I are linked by an amide bond; and The order in which II and I appear in formula (A) can be independently interchanged.

15. The pharmaceutical composition according to claim 14, wherein, n is an integer from 5 to 15, preferably, n is 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, preferably, n is 5, 6, 7, 8, 9, 10, 11 or 12, preferably, n is 5, 6, 7, 8, 9 or 10, preferably, n is 5, 6, 7, 8 or 9, preferably, n is 5, 6, 7 or 8; and / or m is an integer from 1 to 6, preferably, m is 1, 2, 3 or 4, preferably, m is 1 or 2, preferably, m is 1; and / or III is an aliphatic diacid containing 20 to 23 carbon atoms, preferably III is an aliphatic diacid containing 20, 21 or 22 carbon atoms, in which formally a hydroxyl group has been removed from one of the carboxyl groups of the aliphatic diacid; and / or The insulin parent contains one lysine residue.

16. The pharmaceutical composition according to claim 14 or 15, wherein, I is: -HN-(CH2)2-O-(CH2)2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-O-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)4-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-CH2-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-(CH2)2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-(CH2)2-CO-, -HN-(CH2)2-O-(CH2)2-O-(CH2)2-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-CH2-O-CH2-CO-, -HN-(CH2)3-O-(CH2)3-O-CH2-CO-, or -HN-(CH2)4-O-(CH2)4-O-CH2-CO-; preferably I is -HN-(CH2)2-O-(CH2)2-O-CH2-CO-; and / or II is an amino acid residue selected from the following: γGlu, αGlu, βAsp, αAsp, γ-D-Glu, α-D-Glu, β-D-Asp or α-D-Asp; and / or III is HOOC-(CH2) 18 -CO-, HOOC-(CH2) 19 -CO-, HOOC-(CH2) 20 -CO-, HOOC-(CH2) 21 -CO- or HOOC-(CH2) 22 -CO-.

17. The pharmaceutical composition according to any one of claims 14-16, wherein, The formula (A) is linked to the amino group of the lysine residue or the N-terminal amino acid residue of the insulin parent through the C-terminus of I.

18. The pharmaceutical composition according to any one of claims 14-17, wherein, The acyl moiety is linked to the ε-amino group of the lysine residue of the insulin parent.

19. The pharmaceutical composition according to any one of claims 14-18, wherein, The lysine residue of the insulin parent is at position B29.

20. The pharmaceutical composition according to any one of claims 14-19, wherein, The insulin moiety is selected from the following insulins or insulin analogs: desB30 human insulin; A14E, B16H, B25H, desB30 human insulin; A14E, B16E, B25H, desB30 human insulin; human insulin; A21G human insulin; A21G, desB30 human insulin; or B28D human insulin.

21. The pharmaceutical composition according to claim 14, wherein, The acylated insulin is selected from the following insulins: B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-6xOEG-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-βAsp-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-5xOEG-γGlu), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-6xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-βAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-βAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedicarbonyl-αAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl -γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-5xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-6xOEG-γGlu), desB30 human insulin;A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-βAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-βAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-αAsp-6xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-8xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-γGlu-8xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-7xOEG-γGlu), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-8xOEG-γGlu), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-8xOEG-γGlu-γGlu), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-7xOEG-γGlu-γGlu), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-βAsp-7xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-βAsp-8xOEG), desB30 human insulin;B29K(N(ε)-Eicosanedicarbonyl-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-Eicosanedicarbonyl-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-Eicosanedicarbonyl-αGlu-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-Eicosanedicarbonyl-αGlu-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-Eicosanedicarbonyl-αAsp-7xOEG), desB30 human insulin; B29K(N(ε)-Eicosanedicarbonyl-αAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-7xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-8xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-βAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-βAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-Eicosanedicarbonyl-αGlu-αGlu-7xOEG), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-βAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αAsp-8xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-γGlu-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-γGlu-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-5xOEG-γGlu), desB30 human insulin; B29K(N(ε)-docosanoyl-6xOEG-γGlu), desB30 human insulin; B29K(N(ε)-docosanoyl-6xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-docosanoyl-5xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-docosanoyl-βAsp-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-βAsp-6xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-αGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-αGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αAsp-5xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-γGlu-5xOEG), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-5xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-6xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-γGlu-6xOEG), desB30 human insulin;A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-5xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-6xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-6xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-5xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-βAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-βAsp-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αAsp-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αAsp-6xOEG), desB30 human insulin; B29K (N(ε)-docosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-docosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K (N(ε)-docosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-docosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; B29K (N(ε)-docosanedioyl-7xOEG-γGlu), desB30 human insulin; B29K (N(ε)-docosanedioyl-8xOEG-γGlu), desB30 human insulin; B29K (N(ε)-docosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin;B29K(N(ε)-docosanoyl-7xOEG-γGlu-γGlu), desB30 human insulin; B29K(N(ε)-docosanoyl-βAsp-7xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-βAsp-8xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl -αGlu-αGlu-7xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αGlu-αGlu-8xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αAsp-7xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-αAsp-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-7xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-8xOEG-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-βAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-βAsp-8xOEG), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αAsp-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-αAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-γGlu-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-7xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-8xOEG-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-8xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-7xOEG-γGlu-γGlu), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-βAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-βAsp-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedioyl-αGlu-7xOEG), desB30 human insulin;A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αGlu-αGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αGlu-αGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αAsp-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-αAsp-8xOEG), desB30 human insulin; B29K(N(ε)-heneicosanoyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-heneicosanoyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanoyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanoyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanoyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanoyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-heneicosanoyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-heneicosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanoyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanoyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-heneicosanoyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-tricosanoyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-tricosanoyl-γGlu-6xOEG), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-tricosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tricosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tricosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tricosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K (N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tricosanedioyl-γGlu-7xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tricosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K (N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K (N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tetracosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tetracosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K (N(ε)-tetracosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K (N(ε)-tetracosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-tetracosanedioyl-γGlu-7xOEG), desB30 human insulin;A14E, B16H, B25H, B29K(N(ε)-tetracosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-tetracosanoyl-γGlu-7xOEG), desB30 human insulin; or A14E, B16E, B25H, B29K(N(ε)-tetracosanoyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-icosanoyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-docosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-icosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-icosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K(N(ε)-docosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-icosanoyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-icosanoyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-icosanoyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanoyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-heneicosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tricosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-tetracosanoyl-γGlu-12xOEG), desB30 human insulin;A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-9xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-10xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-eicosanedicarbonyl-γGlu-11xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedicarbonyl-γGlu-9xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedicarbonyl-γGlu-10xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-docosanedicarbonyl-γGlu-11xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-heneicosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tricosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; A14E, B16E, B25H, B29K (N(ε)-tetracosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-9xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-10xOEG), desB30 human insulin; B29K (N(ε)-eicosanedicarbonyl-γGlu-11xOEG), desB30 human insulin; B29K (N(ε)-docosanedicarbonyl-γGlu-9xOEG), desB30 human insulin; B29K (N(ε)-docosanedicarbonyl-γGlu-10xOEG), desB30 human insulin; B29K (N(ε)-docosanedicarbonyl-γGlu-11xOEG), desB30 human insulin; B29K (N(ε)-heneicosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; B29K (N(ε)-tricosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; B29K (N(ε)-tetracosanedicarbonyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedicarbonyl-γGlu-18xOEG), desB30 human insulin; or A14E, B16H, B25H, B29K (N(ε)-docosanedicarbonyl-γGlu-24xOEG), desB30 human insulin; Preferably, the acylated insulin is selected from the following insulins: B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-7xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-9xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-9xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-11xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-11xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl -γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-7xOEG), desB30 human insulin;A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-7xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanoyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanoyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-9xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanoyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanoyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-11xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-12xOEG), desB30 human insulin; or A14E, B16H, B25H, B29K (N(ε)-docosanoyl-γGlu-18xOEG), desB30 human insulin; Preferably, the acylated insulin is selected from the following insulins: B29K(N(ε)-eicosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-5xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; B29K(N(ε)-eicosanedioyl-γGlu-8xOEG), desB30 human insulin; B29K(N(ε)-docosanedioyl-γGlu-8xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K(N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; or A14E, B16H, B25H, B29K(N(ε)-docosanedioyl-γGlu-12xOEG), desB30 human insulin; Preferably, the acylated insulin is selected from the following insulins: A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-γGlu-12xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-γGlu-6xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-γGlu-10xOEG), desB30 human insulin; A14E, B16H, B25H, B29K (N(ε)-eicosanedioyl-γGlu-10xOEG), desB30 human insulin; or A14E, B16H, B25H, B29K (N(ε)-docosanedioyl-γGlu-12xOEG), desB30 human insulin.

22. The compound according to any one of claims 1-5, the pharmaceutical preparation according to any one of claims 6-13, or the pharmaceutical composition according to any one of claims 14-21, which is used as a medicine.

23. The compound according to any one of claims 1-5, the pharmaceutical preparation according to any one of claims 6-13, or the pharmaceutical composition according to any one of claims 14-21, which is used for treating or preventing hyperglycemia, diabetes, and / or obesity.

24. Use of the compound according to any one of claims 1-5, the pharmaceutical preparation according to any one of claims 6-13, or the pharmaceutical composition according to any one of claims 14-21 in the preparation of a medicine for treating or preventing hyperglycemia, diabetes, and / or obesity.

25. A method for treating or preventing hyperglycemia, diabetes, and / or obesity, comprising administering a therapeutically effective amount of the compound according to any one of claims 1-5, the pharmaceutical preparation according to any one of claims 6-13, or the pharmaceutical composition according to any one of claims 14-21.